

DCP3 Series Acknowledgments

Disease Control Priorities, third edition (*DCP3*) compiles the global health knowledge of institutions and experts from around the world, a task that required the efforts of over 500 individuals, including volume editors, chapter authors, peer reviewers, advisory committee members, and research and staff assistants. For each of these contributions we convey our acknowledgment and appreciation. First and foremost, we would like to thank our 32 volume editors who provided the intellectual vision for their volumes based on years of professional work in their respective fields, and then dedicated long hours to reviewing each chapter, providing leadership and guidance to authors, and framing and writing the summary chapters. We also thank our chapter authors who collectively volunteered their time and expertise to writing over 170 comprehensive, evidence-based chapters.

We owe immense gratitude to the institutional sponsor of this effort: The Bill & Melinda Gates Foundation. The Foundation provided sole financial support of the Disease Control Priorities Network (DCPN). Many thanks to Program Officers Kathy Cahill, Philip Setel, Carol Medlin, Damian Walker and (currently) David Wilson for their thoughtful interactions, guidance, and encouragement over the life of the project. We also wish to thank Jaime Sepúlveda for his longstanding support, including chairing the Advisory Committee for the second edition and, more recently, demonstrating his vision for *DCP3* while he was a special advisor to the Gates Foundation. We are also grateful to the University of Washington's Department of Global Health and successive chairs King Holmes and Judy Wasserheit for providing a home base for the *DCP3* Secretariat, which included intellectual collaboration, logistical coordination, and administrative support.

We thank the many contractors and consultants who provided support to specific volumes in the form of economic analytical work, volume coordination, chapter drafting, and meeting organization: the Center for Disease Dynamics, Economics & Policy; Center for Chronic Disease Control; Centre for Global Health Research; Emory University; Evidence to Policy Initiative; Public Health Foundation of India; QURE Healthcare; University of California, San Francisco; University of Waterloo; University of Queensland; and the World Health Organization.

We are tremendously grateful for the wisdom and guidance provided by our advisory committee to the editors. Steered by Chair Anne Mills, the advisory committee ensures quality and intellectual rigor of the highest order for *DCP3*.

The National Academies of Sciences, Engineering, and Medicine, in collaboration with the Interacademy Medical Panel, coordinated the peer-review process for all *DCP3* chapters. Patrick Kelley, Gillian Buckley, Megan Ginivan, Rachel Pittluck, and Tara Mainero managed this effort and provided critical and substantive input.

World Bank Publishing provided exceptional guidance and support throughout the demanding production and design process. We would particularly like to thank Carlos Rossel, Mary Fisk, Nancy Lammers, Runit Pancholi, Deborah Naylor, and Sherrie Brown for their diligence and expertise. Additionally, we thank Jose de Buerba, Mario Trubiano, Yulia Ivanova, and Chiamaka Osuagwu of the World Bank for providing professional counsel on communications and marketing strategies.

Several U.S. and international institutions contributed to the organization and execution of meetings that supported the preparation and dissemination of *DCP3*.

We would like to express our appreciation to the following institutions:

- University of Bergen, consultation on equity (June 2011)
- University of California, San Francisco, surgery volume consultations (April 2012, October 2013, February 2014)
- Institute of Medicine, first meeting of the Advisory Committee to the Editors (March 2013)
- Harvard Global Health Institute, consultation on policy measures to reduce incidence of noncommunicable diseases (July 2013)
- National Academy of Medicine, systems strengthening meeting (September 2013)
- Center for Disease Dynamics, Economics & Policy (Quality and Uptake meeting, September 2013; reproductive and maternal health volume consultation, November 2013)
- National Cancer Institute, cancer consultation (November 2013)
- Union for International Cancer Control, cancer consultation (November 2013, December 2014)
- Harvard T. H. Chan School of Public Health, economic evaluation consultation (September 2015)
- University of California, Berkeley School of Public Health, and Stanford Medical School, occupational and environmental health consultations (December 2015).

Carol Levin provided outstanding governance for cost and cost-effectiveness analysis. Stéphane Verguet added valuable guidance in applying and improving the extended cost-effectiveness analysis method. Elizabeth Brouwer, Kristen Danforth, Nazila Dabestani, Shane Murphy, Zachary Olson, Jinyuan Qi, and David Watkins provided exceptional research assistance and analytic assistance. Brianne Adderley ably managed the budget and project processes, while Jennifer Nguyen, Shamelle Richards, and Jennifer Grasso contributed exceptional project coordination support. The efforts of these individuals were absolutely critical to producing this series, and we are thankful for their commitment.

Volume and Series Editors

VOLUME EDITORS

Dorairaj Prabhakaran

Dorairaj Prabhakaran, MD, DM (Cardiology), MSc, FRCP, FNAsc, is a cardiologist and epidemiologist, with special interest in genetic epidemiology. Until recently, he was Professor at All India Institute of Medical Sciences; he currently heads the Center for Chronic Disease Control and is Professor of Chronic Disease Epidemiology at the Public Health Foundation of India. He is the Head of the Center of Excellence—Center for Cardio-metabolic Risk Reduction in South Asia (CoE-CARRS) located in the Public Health Foundation of India and funded by the National Heart, Lung, and Blood Institute. He is also a consultant to the World Bank, the World Health Organization (WHO), and other international organizations and is a reviewer for several international and national journals. He is associate editor of *Journal of Epidemiology and Community Health* and member of the Editorial Advisory Board of Clinical Science. He has more than 100 publications in several high-impact journals, such as the *New England Journal of Medicine*, *The Lancet*, the *Journal of the American Medical Association*, and the *Journal of American College of Cardiology*.

Shuchi Anand

Shuchi Anand, MD, is an Instructor of Medicine at Stanford University School of Medicine, with a research focus on chronic kidney disease epidemiology and management in low-resource settings. She is a former Fogarty Scholar, and a current recipient of National Institute for Diabetes and Digestive and Kidney Diseases Career Development award. She is studying epidemiology and management of chronic kidney disease in urban India,

dialysis practices in China, and the epidemic of chronic kidney disease in Sri Lanka.

Thomas A. Gaziano

Thomas A. Gaziano, MD, MSc, is jointly appointed to the Divisions of Cardiovascular Medicine and Social Medicine and Health Inequalities at Brigham & Women's Hospital, Harvard Medical School, and the Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Cambridge, Massachusetts. He is certified as a Diplomat in Internal Medicine and Cardiovascular Diseases and has expertise in the treatment of cardiovascular diseases (CVD) in low- and middle-income countries, including the epidemiology and management of its risk factors. His research includes the development of decision analytic models to assess the cost-effectiveness of various screening, prevention, and management decisions. His international experience includes two years at Oxford University South Africa as the first *Lancet* International Fellow and four months in India evaluating CVD epidemiology and cost-effective strategies for its management. He has served as a consultant and author for the Disease Control Priorities Project organized by the World Bank; the WHO; and the Fogarty International Center, National Institutes of Health, and has been funded by the Bill & Melinda Gates Foundation.

Jean-Claude Mbanya

Jean-Claude Mbanya is Professor of Medicine and Endocrinology at the Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Cameroon; Consultant Physician, Director of the Health in

Transition Research Group, and Director of the National Obesity Centre, University of Yaoundé, Cameroon; and Chief of the Endocrinology and Metabolic Diseases Unit at the Hospital Central in Yaoundé. Professor Mbanya served as President of the International Diabetes Federation (IDF) from 2009 to 2012. He was instrumental in the IDF-led Unite for Diabetes campaign, which led to the passage of the United Nations Day Resolution on Diabetes in December 2006. He now steers IDF strategic direction to encourage governments to implement policies for the treatment, care, and prevention of diabetes. His research mainly focuses on cultural diabetes-related factors, which are often unique to the Sub-Saharan African countries and communities he studies. His practice and research have largely contributed to increase the world's awareness on diabetes in this region.

Rachel Nugent

Rachel Nugent is Vice President for Global Noncommunicable Diseases at RTI International. She was formerly a Research Associate Professor and Principal Investigator of the DCPN in the Department of Global Health at the University of Washington. Previously, she served as Deputy Director of Global Health at the Center for Global Development, Director of Health and Economics at the Population Reference Bureau, Program Director of Health and Economics Programs at the Fogarty International Center of the National Institutes of Health, and senior economist at the Food and Agriculture Organization of the United Nations. From 1991 to 1997, she was associate professor and department chair in economics at Pacific Lutheran University.

Yangfeng Wu

Yangfeng Wu is the Director of The George Institute, China. He is also the Executive Associate Director, Peking University Clinical Research Institute. A cardiovascular specialist, Professor Wu is responsible for the scientific program in China, which includes all areas of noncommunicable disease and injuries. Professor Wu has made valuable contributions to reduce the impact of cardiovascular disease in the region with his work at Fu Wai Hospital; the WHO Collaborating Center in Cardiovascular Disease Prevention, Control, and Research, China; and Peking University. While the director of the WHO Collaborating Center in Cardiovascular Disease Prevention, Control, and Research in China, he has reported on hypertension control in low- and

middle-income countries, including reducing salt intake in populations.

SERIES EDITORS

Dean T. Jamison

Dean T. Jamison is an Emeritus Professor of Global Health at the University of Washington and an Emeritus Professor of Global Health Sciences at the University of California, San Francisco. He previously held academic appointments at Harvard University and the University of California, Los Angeles, and he was an economist on the staff of the World Bank, where he was lead author of the World Bank's *World Development Report 1993: Investing in Health*. He was the lead editor of *DCP2*. He holds a PhD in economics from Harvard University and is an elected member of the Institute of Medicine of the U.S. National Academies. He recently served as Co-Chair and Study Director of *The Lancet's* Commission on Investing in Health.

Rachel Nugent

See the list of Volume Editors.

Hellen Gelband

Hellen Gelband is an independent global health policy expert. Her work spans infectious disease, particularly malaria and antibiotic resistance, and noncommunicable disease policy, mainly in low- and middle-income countries. She has conducted policy studies at Resources for the Future, the Center for Disease Dynamics, Economics & Policy, the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations.

Susan Horton

Susan Horton is Professor at the University of Waterloo and holds the Centre for International Governance Innovation (CIGI) Chair in Global Health Economics in the Balsillie School of International Affairs there. She has consulted for the World Bank, the Asian Development Bank, several United Nations agencies, and the International Development Research Centre, among others, in work conducted in over 20 low- and middle-income countries. She led the work on nutrition for the Copenhagen Consensus in 2008, when micronutrients were ranked as the top development priority. She has served as associate provost of graduate

studies at the University of Waterloo, vice-president academic at Wilfrid Laurier University in Waterloo, and interim dean at the University of Toronto at Scarborough.

Prabhat Jha

Prabhat Jha is the founding director of the Centre for Global Health Research at St. Michael's Hospital and holds Endowed and Canada Research Chairs in Global Health in the Dalla Lana School of Public Health at the University of Toronto. He is lead investigator of the Million Death Study in India, which quantifies the causes of death and key risk factors in over two million homes over a 14-year period. He is also Scientific Director of the Statistical Alliance for Vital Events, which aims to expand reliable measurement of causes of death worldwide. His research includes the epidemiology and economics of tobacco control worldwide.

Ramanan Laxminarayan

Ramanan Laxminarayan is Vice President for Research and Policy at the Public Health Foundation of India, and he directs the Center for Disease Dynamics, Economics & Policy in Washington, DC, and New Delhi. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He was

one of the key architects of the Affordable Medicines Facility—malaria, a novel financing mechanism to improve access and delay resistance to antimalarial drugs. In 2012, he created the Immunization Technical Support Unit in India, which has been credited with improving immunization coverage in the country. He teaches at Princeton University.

Charles N. Mock

Charles N. Mock, MD, PhD, FACS, has training as both a trauma surgeon and an epidemiologist. He worked as a surgeon in Ghana for four years, including at a rural hospital (Berekum) and at the Kwame Nkrumah University of Science and Technology (Kumasi). In 2005–07, he served as Director of the University of Washington's Harborview Injury Prevention and Research Center. In 2007–10, he worked at the WHO headquarters in Geneva, where he was responsible for developing the WHO's trauma care activities. In 2010, he returned to his position as Professor of Surgery (with joint appointments as Professor of Epidemiology and Professor of Global Health) at the University of Washington. His main interests include the spectrum of injury control, especially as it pertains to low- and middle-income countries: surveillance, injury prevention, prehospital care, and hospital-based trauma care. He was President (2013–15) of the International Association for Trauma Surgery and Intensive Care.

Contributors

Alma Adler

Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom

Ashkan Afshin

Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States

Vamadevan S. Ajay

Centre for the Control of Chronic Conditions; Public Health Foundation of India, New Delhi, India

Mohammed K. Ali

Rollins School of Public Health, Emory University, Atlanta, Georgia, United States

Shuchi Anand

Stanford University School of Medicine, Stanford, California, United States

Eric Bateman

Division of Pulmonology, Department of Medicine, University of Cape Town, South Africa

Janet Bettger

Department of Orthopaedic Surgery, Duke University; Duke Clinical Research Institute; Duke Global Health Institute, Durham, North Carolina, United States

Robert O. Bonow

Center for Cardiovascular Innovation, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States

Elizabeth Brouwer

University of Washington, Seattle, Washington, United States

Gene Buhkman

Department of Global Health & Social Medicine, Harvard University; Division of Cardiovascular Medicine, Harvard Medical School; Partners in Health, Boston, Massachusetts, United States

Fiona Bull

Centre for the Built Environment and Health, The University of Western Australia, Crawley, Western Australia, Australia

Peter Burney

National Heart & Lung Institute, Imperial College London, London, United Kingdom

Simon Capewell

Institute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom

Juliana Chan

MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom; Hong Kong Institute of Diabetes and Obesity; International Diabetes Federation Centre of Education; The Chinese University of Hong Kong—Prince of Wales Hospital, Hong Kong SAR, China

Eeshwar K. Chandrasekar

Emory University School of Medicine, Atlanta, Georgia, United States

Jie Chen

Shanghai Advanced Institute of Finance, Shanghai Jiao Tong University, Shanghai, China

Michael H. Criqui

Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California—San Diego School of Medicine, La Jolla, California, United States

John Dirks

Gardner Foundation (Emeritus President);
Massey College, University of Toronto, Toronto,
Ontario, Canada

Chandrasagar B. Dugani

Department of Medicine, and Division of Cardiology,
Brigham and Women's Hospital; Harvard Medical
School, Boston, Massachusetts, United States;
St. Michael's Hospital; University of Toronto,
Toronto, Ontario, Canada

Michael Engelgau

Center for Translation Research and Implementation
Science, National Heart Lung and Blood Institute,
National Institutes of Health, Bethesda, Maryland,
United States

Meguid El Nahas

Sheffield Kidney Institute; Global Kidney Academy,
Sheffield, United Kingdom

Caroline H. D. Fall

MRC Lifecourse Epidemiology Unit, University of
Southampton, Southampton, United Kingdom

Valery Feigin

National Institute of for Stroke and Applied
Neurosciences, Auckland University of Technology,
Auckland, New Zealand

F. Gerald R. Fowkes

Usher Institute of Population Health Sciences and
Informatics, University of Edinburgh, Edinburgh,
United Kingdom

Thomas A. Gaziano

Harvard Medical School, Harvard T. H. Chan School of
Public Health; Brigham and Women's Hospital, Boston,
Massachusetts, United States

Amanda Glassman

Center for Global Development, Washington, DC,
United States

Shifalika Goenka

Public Health Foundation of India, New Delhi, India

Rajeev Gupta

Fortis Escorts Hospital, New Delhi, India

Babar Hasan

Department of Paediatric and Child Health, The Aga
Khan University, Karachi, Pakistan

Fred Hersch

School of Public Health, Sydney Medical School,
University of Sydney, Sydney, Australia

Frank Hu

Harvard T. H. Chan School of Public Health, Boston,
Massachusetts, United States

Mark D. Huffman

Feinberg School of Medicine, Northwestern University,
Chicago, Illinois, United States

Samer Jabbour

Faculty of Health Sciences, American University of
Beirut, Beirut, Lebanon

Deborah Jarvis

National Heart & Lung Institute, Imperial College
London, London, United Kingdom

Panniyammakal Jeemon

Center for Control of Chronic Conditions, Public
Health Foundation of India, New Delhi, India

Rohina Joshi

The George Institute for Global Health; Faculty of
Medicine, University of Sydney, Sydney, Australia

Jemima H. Kamano

Department of Medicine, Moi University School of
Medicine; The Academic Model Providing Access to
Healthcare, Eldoret, Kenya

Andre Pascal Kengne

South African Medical Research Council, Tygerberg,
South Africa

Preeti Kudesia

Health, Nutrition, and Population Global Practice,
World Bank, Washington, DC, United States

R. Krishna Kumar

Department of Pediatric Cardiology, Amrita Institute
of Medical Sciences and Research Centre, Cochin, India

Kalyanaraman Kumaran

MRC Lifecourse Epidemiology Unit, University of
Southampton, Southampton, United Kingdom;
Epidemiology Research Unit, CSI Holdsworth
Memorial Hospital, Mysore, India

Estelle V. Lambert

Division of Exercise Science and Sports Medicine,
Department of Human Biology, Faculty of Health Sciences,
University of Cape Town, Cape Town, South Africa

Edward S. Lee

Keck School of Medicine, University of Southern
California, Los Angeles, California, United States

Carol Levin

Department of Global Health, University of
Washington, Seattle, Washington, United States

Chaoyun Li

Global Health Research Center, Duke Kunshan University, Kunshan, China

Rong Luo

The George Institute for Global Health, Peking University Health Science Center, Beijing, China

Matthew Magee

Georgia State University School of Public Health, Atlanta, Georgia, United States

Vasanti S. Malik

Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

J. Antonio Marin-Neto

Medical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

Guy Marks

South Western Sydney Clinical School, University of New South Wales, Liverpool, New South Wales, Australia

Bongani Mayosi

Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

Jean-Claude Mbanya

Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon

Helen McGuire

PATH, Seattle, Washington, United States

Renata Micha

Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, United States

J. Jaime Miranda

CRONICAS Center of Excellence for Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru

Pablo Aschner Montoya

MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom; Javeriana University School of Medicine; San Ignacio University Hospital; Colombian Diabetes Association, Bogotá, Colombia

Andrew E. Moran

Division of General Medicine, Department of Medicine, Columbia University Medical Center, New York, New York, United States

Dariush Mozaffarian

Friedman School of Nutrition Science & Policy, Tufts University, Boston, Massachusetts, United States

Saraladevi Naicker

School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa

Nadraj G. Naidoo

University of Cape Town, Cape Town, South Africa

K. M. Venkat Narayan

Rollins School of Public Health, Emory University, Atlanta, Georgia, United States

Irina Nikolic

Division of Health, Nutrition, and Population Global Practice, World Bank, Washington, DC, United States

Rachel Nugent

Research Triangle Institute International, Research Triangle Park, North Carolina; Research Triangle Institute, Seattle, Washington, United States

Martin O'Donnell

National University of Ireland Galway, Galway, Ireland

Churchill Onen

Diabetes Association of Botswana, Gaborone, Botswana

Clive Osmond

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, United Kingdom

Anushka Patel

University of Sydney, Sydney, Australia

Rogelio Perez-Padilla

National Institute of Respiratory Diseases of Mexico, Mexico City, Mexico

Neil Poulter

National Heart & Lung Institute, Imperial College London, London, United Kingdom

Dorairaj Prabhakaran

Centre for Chronic Disease Control; Public Health Foundation of India, New Delhi, India

Michael Pratt

National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention; Emory University, Atlanta, Georgia, United States

Miriam Rabkin

ICAP at Columbia, Mailman School of Public Health, Columbia University, New York, New York, United States

Vikram Rajan

World Bank, New Delhi, India

Anis Rassi

Anis Rassi Hospital, Goiânia, Brazil

Anis Rassi Jr.

Anis Rassi Hospital, Goiânia, Brazil

Ishita Rawal

Centre for Chronic Disease Control, New Delhi, India

Giuseppe Remuzzi

Istituto di Ricerche Farmacologiche Mario Negri,
Centro Maria Astori; Bergamo, Italy

Miguel Riella

Evangelic School of Medicine; Evangelic University
Hospital; Pro-Renal Brazil Foundation Curitiba, Parana,
Brazil

Greg A. Roth

Division of Cardiology, Department of Medicine,
School of Medicine, University of Washington, Seattle,
Washington, United States

Ambuj Roy

All India Institute of Medical Sciences, New Delhi,
India

Adolfo Rubinstein

South American Center of Excellence in Cardiovascular
Health; Institute for Clinical Effectiveness and Health
Policy; School of Medicine, University of Buenos Aires,
Buenos Aires, Argentina

Yuna Sakuma

Center for Global Development, Washington, DC,
United States

Uchechukwu K. A. Sampson

National Heart, Lung, and Blood Institute, National
Institutes of Health, Bethesda, Maryland, United States

Karen R. Siegel

Emory University, Atlanta, Georgia, United States

Karen Sliwa

Hatter Institute for Cardiovascular Research in Africa,
University of Cape Town, Cape Town, South Africa

Marc Suhrcke

Centre for Health Economics, University of York, York,
United Kingdom

Nikhil Tandon

All India Institute of Medical Sciences; Centre for
Chronic Disease Control, New Delhi, India

Bernadette Thomas

Institute for Health Metrics and Evaluation, University
of Washington, Seattle, Washington, United States

Claudia Vaca

Ministry of Health, Bogotá, Colombia

Rajesh Vedanthan

Icahn School of Medicine at Mount Sinai, New York,
New York, United States

Stéphane Verguet

Department of Global Health and Population, Harvard
T. H. Chan School of Public Health, Boston,
Massachusetts, United States

David A. Watkins

Departments of Medicine and Global Health, University
of Washington, Seattle, Washington, United States

Michael Webb

Stanford University, Palo Alto, California, United States

Mary Beth Weber

Emory Global Diabetes Research Center, Hubert
Department of Global Health, Emory University,
Atlanta, Georgia, United States

Laurie Whitsel

American Heart Association, Washington, DC,
United States

Gary Wong

Prince of Wales Hospital, The Chinese University of
Hong Kong, Shatin, Hong Kong SAR, China

Yangfeng Wu

The George Institute for Global Health, Peking
University Health Science Center; Department of
Epidemiology and Biostatistics, Peking University
School of Public Health, Beijing, China

Lijing L. Yan

Global Health Research Center, Duke Kunshan
University; The George Institute for Global Health,
Peking University Health Science Center, Beijing, China

Clyde W. Yancy

Feinberg School of Medicine, Northwestern University,
Chicago, Illinois, United States

Ping Zhang

Centers for Disease Control and Prevention, Atlanta,
Georgia, United States

Dong Zhao

Department of Epidemiology, Beijing Anzhen Hospital,
Capital Medical University, Beijing, China

Yishan Zhu

National School of Development, Peking University,
Beijing, China

Advisory Committee to the Editors

Anne Mills, Chair

Professor, London School of Hygiene & Tropical Medicine, London, United Kingdom

Olusoji Adeyi

Director, Health, Nutrition and Population Global Practice, World Bank, Washington, DC, United States

Kesetebirhan Admasu

Former Minister of Health, Addis Ababa, Ethiopia

George Alleyne

Director Emeritus, Pan American Health Organization, Washington, DC, United States

Ala Alwan

Regional Director Emeritus, World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

Rifat Atun

Professor, Global Health Systems, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Zulfiqar Bhutta

Chair, Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Agnes Binagwaho

Former Minister of Health, Kigali, Rwanda

Mark Blecher

Senior Health Advisor, South Africa Treasury Department, Cape Town, South Africa

Patricia Garcia

Minister of Health, Lima, Peru

Roger Glass

Director, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States

Amanda Glassman

Chief Operating Officer and Senior Fellow, Center for Global Development, Washington, DC, United States

Glenda Gray

Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Demissie Habte

Chair of Board of Trustees, International Clinical Epidemiological Network, Addis Ababa, Ethiopia

Richard Horton

Editor, *The Lancet*, London, United Kingdom

Edward Kirumira

Dean, Faculty of Social Sciences, Makerere University, Kampala, Uganda

Peter Lachmann

Professor, University of Cambridge, Cambridge, United Kingdom

Lai Meng Looi

Professor, University of Malaya, Kuala Lumpur, Malaysia

Adel Mahmoud

Senior Molecular Biologist, Princeton University, Princeton, New Jersey, United States

Anthony Measham

World Bank (retired)

Carol Medlin

Independent Consultant, Washington, DC, United States

Alvaro Moncayo

Researcher, Universidad de los Andes, Bogotá, Colombia

Jaime Montoya

Executive Director, Philippine Council for Health Research and Development, Taguig City, the Philippines

Ole Norheim

Professor, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

Folashade Omokhodion

Professor, University College Hospital, Ibadan, Nigeria

Toby Ord

President, Giving What We Can, Oxford, United Kingdom

K. Srinath Reddy

President, Public Health Foundation of India, New Delhi, India

Sevket Ruacan

Dean, Koç University School of Medicine, Istanbul, Turkey

Jaime Sepúlveda

Executive Director, Global Health Sciences, University of California, San Francisco, San Francisco, California, United States

Richard Skolnik

Yale University School of Public Health (retired)

Stephen Tollman

Professor, University of Witwatersrand, Johannesburg, South Africa

Jürgen Unutzer

Professor, Department of Psychiatry, University of Washington, Seattle, Washington, United States

Damian Walker

Deputy Director of Data and Analytics, Bill & Melinda Gates Foundation, Seattle, Washington, United States

Ngairé Woods

Director, Global Economic Governance Program, Oxford University, Oxford, United Kingdom

Nopadol Wora-Urai

Professor, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand

Kun Zhao

Researcher, China National Health Development Research Center, Beijing, China

Reviewers

Olusoji Adeyi

Director, Health, Nutrition, and Population Global Practice, World Bank, Washington, DC, United States

Kamel Ajlouni

The National Center for Diabetes, Endocrinology and Genetics; The University of Jordan, Amman, Jordan

Wael K. Al-Delaimy

University of California–San Diego, La Jolla, California, United States

Valter Cordeiro Barbosa Filho

Research Centre in Physical Activity and Health, Federal University of Santa Catarina, Florianópolis, Brazil

Robert Beaglehole

International Public Health Consultants, Auckland, New Zealand

Digambar Behera

Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research; WHO Collaborating Centre for Research and Capacity Building in Chronic Respiratory Diseases, Chandigarh, India

Liwei Chen

Clemson University, Clemson, South Carolina, United States

Valentin Fuster

The Mount Sinai Medical Hospital; Mount Sinai Heart; Icahn School of Medicine at Mount Sinai, New York, New York, United States

Guillermo Garcia-Garcia

Hospital Civil de Guadalajara “Fray Antonio Alcalde,” University of Guadalajara Health Sciences Center, Guadalajara, Mexico

Scott Kahan

National Center for Weight and Wellness, Washington, DC, United States; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

Jonathan Kaltman

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States

Eduardo M. Krieger

Heart Institute, Medical School of the University of São Paulo (InCor-FMUSP), São Paulo, Brazil

Harriet V. Kuhnlein

Centre for Indigenous Peoples’ Nutrition and Environment and School of Dietetics and Human Nutrition, McGill University, Montreal, Canada

Anuradha Lala

Icahn School of Medicine at Mount Sinai; The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York, United States

Naomi Levitt

University of Cape Town; Chronic Disease Initiative for Africa, Cape Town, South Africa

Carlos Mendoza Montano

Institute of Nutrition of Central America and Panama (INCAP); INCAP Research Center for the Prevention of Chronic Diseases, Guatemala City, Guatemala

George A. Mensah

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States

Andrew J. Mirelman

Centre for Health Economics, University of York, York, United Kingdom

Monica L. Mispireta

School of Nursing, Idaho State University, Pocatello, Idaho, United States

Jorge A. Motta

National Secretary Science, Technology and Innovation, Panama City, Panama

Jagat Narula

Journal of the American College of Cardiology, Washington, DC, United States; Arnhold Institute for Global Health at Mount Sinai; Icahn School of Medicine at Mount Sinai; Mount Sinai West and Mount Sinai St. Luke's Hospitals, New York, New York, United States

Frida Ngalesoni

University of Bergen, Bergen, Norway

Ole Frithjof Norheim

University of Bergen, Bergen, Norway

Pekka Puska

National Institute for Health and Welfare (THL), Helsinki, Finland

Cristina Rabadan-Diehl

Office of the Americas, Office of Global Affairs, United States Department of Health and Human Services, Washington, DC, United States

K. Srinath Reddy

Public Health Foundation of India, New Delhi, India

Rebecca Reynolds

University of Edinburgh, Edinburgh, United Kingdom

Jonathan M. Samet

Keck School of Medicine, University of Southern California (USC); USC Institute for Global Health, Los Angeles, California, United States

John W. Stanifer

Duke University; Duke Clinical Research Institute; Duke Global Health Institute, Durham, North Carolina, United States

Nigel Unwin

Chronic Disease Research Centre, University of the West Indies, Barbados; MRC Epidemiology Unit, Cambridge University, Cambridge, United Kingdom

Martin Veller

University of the Witwatersrand, Johannesburg, South Africa

S. Goya Wannamethee

University College London Medical School, London, United Kingdom

Kremlin Wickramasinghe

Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom

Edwina H. Yeung

Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States

Policy Forum Participants

The following individuals provided valuable insights to improve this volume's key findings through participation in the Disease Control Priorities-World Health Organization, Eastern Mediterranean Regional Office policy forum on Cardiovascular Disease and Diabetes, in Geneva, Switzerland, on November 14, 2015. The forum was organized by Dr. Ala Alwan, Regional Director, World Health Organization, and member of the DCP3 Advisory Committee to the Editors.

Ala Alwan

Regional Director Emeritus, World Health Organization
Regional Office for the Eastern Mediterranean, Cairo,
Arab Republic of Egypt

Fawzi Amin

Secretary General, Bahrain Red Crescent Society; Former
Director General of Primary Health Care and Assistant
Undersecretary, Ministry of Health, Manama, Bahrain

Walid Ammar

Director General, Ministry of Public Health, Beirut,
Lebanon

Karim Aoun

Director General, Ministry of Health, Tunisia; Professor
in Parasitology, Medical School of Tunis, Tunis, Tunisia

Nooshin Mohd Bazargani

Deputy Head of Dubai Heart Centre, Dubai, United
Arab Emirates; Board Member of World Heart
Federation, Geneva, Switzerland; Chair, CVD
Prevention Group of Emirates Cardiac Society,
Abu Dhabi, United Arab Emirates

Suraya Dalil

Permanent Representative of the Government of the
Islamic Republic of Afghanistan to the United Nations,
Geneva, Switzerland; Former Minister of Health, Kabul,
Afghanistan

Reida M. A. Elaokley

Minister of Health, Ministry of Health,
El-Beida, Libya

Hassen Ghannem

Director, Tunisia Center of Excellence to
Combat Chronic Diseases, Department of
Epidemiology, University Hospital Farhat Hached,
Sousse, Tunisia

Assad Hafeez

Director General of Health, Ministry of National
Health Services, Regulation, and Coordination,
Islamabad, Pakistan

Ali bin Talib Al Hinai

Undersecretary for Planning, Ministry of Health,
Muscat, Oman

Didier Houssin

President, High Council for the Evaluation of
Research and Higher Education, Paris, France;
Former Director General for Health, Ministry of
Health, Paris, France

Azhar Mahmood Kayani

Consultant Cardiologist, Army Medical College,
Rawalpindi, Pakistan

Sa'ad Kharabsheh

Former Minister of Health, Amman, Jordan

Bagher Ardeshir Larijani

Deputy Minister for Education; Head of High Level NCD Council, Ministry of Health and Medical Education, Tehran, Islamic Republic of Iran

Pekka Puska

Former Director General, The National Institute for Health and Welfare, Helsinki, Finland

Ali Faraj Al-Qaraghuli

Senior Consultant Cardiologist, Al Oyoun Hospital, Amman, Jordan

Junaid Razzak

Director, Telemedicine Programme and Senior Advisor Global Health, Department of Emergency Medicine, Johns Hopkins University School of Medicine; Department

of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States; Visiting Faculty, Department of Emergency Medicine, Aga Khan University, Karachi, Pakistan

Qasim Bin Ahmad Al Salimi

Director General, The Royal Hospital, Muscat, Oman

Amirhossein Takian

Deputy Acting Minister for International Affairs, Ministry of Health and Medical Education, Tehran, Islamic Republic of Iran

Mohammed Hamad J. Al-Thani

Director of Public Health, Department of Public Health, Ministry of Public Health, Doha, Qatar

Index

Boxes, figures, maps, notes, and tables are indicated by *b*, *f*, *m*, *n*, and *t* following page numbers.

A

- abdominal obesity, 28–29. *See also* obesity/
overweight
- Academia de Cidade (Brazil), 90*b*
- Academic Model Providing Access to Healthcare
(AMPATH), 331
- ACE inhibitors. *See* angiotensin-converting enzyme
inhibitors
- ACE Obesity Study, 127–29, 128*t*
- acute coronary syndrome (ACS), 136, 140–43,
328–29, 333–35, 338, 340, 360
- acute kidney injury (AKI), 15, 178, 235–39,
237*b*, 242, 383
- acute rheumatic fever (ARF), 197–200, 357
- ADA. *See* American Diabetes Association
- adherence to treatment
 - chronic respiratory diseases, 270, 272–73
 - community-based care and, 315, 321
 - cost-effectiveness of interventions and, 358
 - costs and, 356–58
 - diabetes, 218, 223
 - heart failure, 182, 186
 - hypertension, 163, 395, 397
 - integrated care and, 296–97
 - ischemic heart disease, 142, 144, 146
 - obesity interventions, 126
 - quality of care and, 330, 333, 334–36, 338–39, 341
 - rheumatic heart disease, 198, 202
 - stroke, 160
- Adler, Alma, 389
- adolescence, BMI in, 42–43
- Africa. *See also specific countries*
 - congenital heart disease in, 194
 - cost-effectiveness of interventions in, 353
 - diabetes in, 211, 216
 - diet and nutrition in, 106
 - heart failure in, 175, 185
 - ischemic heart disease in, 138–40, 142–43
 - kidney disease in, 236
 - obesity/overweight in, 120
 - priority-setting for treatments in, 379
 - quality of care in, 338, 340, 342
 - rheumatic heart disease in, 200
 - tobacco use in, 68
- Afshin, Ashkan, 101
- Agita São Paulo (Brazil), 90*b*
- AIDS. *See* HIV/AIDS
- Ajay, Vamadevan S., 23, 287
- AKI. *See* acute kidney injury
- Ali, Mohammed K., 209, 287
- Allen, K., 110
- Alzheimer’s disease, 64–65
- American College of Cardiology, 174*b*
- American College of Sports Medicine, 89
- American Diabetes Association (ADA), 85, 214–15, 217
- American Heart Association, 162, 174*b*
- American Stroke Association, 162
- AMPATH (Academic Model Providing Access to
Healthcare), 331
- Amrita Institute of Medical Sciences (India), 196
- Anand, Shuchi, 1, 235
- angina, 136
- angiotensin-converting enzyme (ACE) inhibitors, 12,
141, 178–79, 181–84, 186, 215, 242, 247, 393, 395
- angiotensin receptor blockers (ARBs), 7, 15, 142, 145,
178, 215, 219, 222, 242–43, 247, 357, 391–92
- antibiotics, 237, 274–76
- anticoagulation therapies, 164–65, 179, 186
- antihypertensive treatments, 163, 165, 186, 393
- antiplatelet therapy, 166, 393

- aortic artery disease, 66
 ARBs. *See* angiotensin receptor blockers
 ARF. *See* acute rheumatic fever
 Argentina
 Chagas disease in, 204
 cost-effectiveness of interventions in, 353, 359
 diet and nutrition in, 108, 110
 heart failure in, 184
 ischemic heart disease in, 141, 147
 priority-setting for treatments in, 378–83
 quality of care in, 342
 stroke in, 165
 Armour, T. A., 314
 arrhythmia, 64, 66, 178
 Asaria, P., 110
 aspirin, 141–46, 164, 166, 179, 185, 254, 329, 333, 336, 341, 357–59, 375, 389, 393, 395
 asthma
 assessment, 271–72
 barriers to care, 272–73
 burden of disease, 263–65
 community-based care, 307–8
 diagnosis, 271
 management of, 272, 277, 308, 310
 mortality and morbidity trends, 27
 pharmacological management, 272
 prevention, 269
 risk factors, 263–65
 symptoms, 27, 271–72
 atenolol, 8, 142, 178, 392–93
 atherosclerosis, 58*b*
 atherothrombosis, 58*b*
 atrial fibrillation, 64, 66, 160–64, 179, 197, 398
 Australia
 Chagas disease in, 203
 chronic respiratory diseases in, 264
 community-based care in, 305, 311
 diabetes in, 216
 diet and nutrition in, 106
 ischemic heart disease in, 144, 146
 obesity/overweight in, 126–27, 129
 physical activity in, 87–88
- B**
 Bakshi, K. D., 196
 Bangladesh
 cardiometabolic disease in, 46–47
 community-based care in, 310
 cost-effectiveness of interventions in, 356
 hypertension in, 397
 bariatric surgery, 127
 Barker, D. J. P., 37, 39
 Barthel Index, 168, 316
 Bateman, Eric, 263
 Belarus
 breastfeeding promotion in, 47
 ischemic heart disease in, 138
 beta blockers, 6, 9–10, 141–46, 163, 177–79, 181, 183–86, 254, 317, 333, 358–59, 391–93, 395
 Bettger, Janet, 157
 bidi smoking, 68. *See also* tobacco use
 birth weight
 cardiometabolic disease and, 37–40, 43–46, 48
 low birth weight, 30–31, 37, 39, 43–45, 241, 267–68
 bisphenol, 44
 blood pressure (BP)
 cardiometabolic disease and, 39–40, 42, 44–47
 community-based care and, 308–10, 314–15, 319, 321
 cost-effectiveness of interventions, 356–58
 diabetes and, 214, 216–17
 integrated care and, 295, 297
 kidney disease and, 243–44
 management of, 389, 391–92, 395, 397–98
 physical activity and, 84–85, 91
 quality of care and, 330, 336–38, 340
 as risk factor, 28–30
 stroke and, 161, 163–65, 166
 tobacco use and, 60, 62–63, 66, 70
 BMI. *See* body mass index
 body fat. *See also* obesity/overweight
 cardiometabolic disease and, 40–41
 obesity/overweight and, 117–18
 physical activity and, 91
 body mass index (BMI)
 cardiometabolic disease and, 37, 39, 41–43, 47–48
 chronic respiratory diseases and, 264
 diet and, 104
 integrated care and, 292
 obesity/overweight and, 117–19, 123, 128
 physical activity and, 83–86
 priority-setting for treatments, 385
 Bonow, Robert O., 135
 Boston University, 241*b*
 BP. *See* blood pressure
 Brazil
 Chagas disease in, 204
 chronic respiratory diseases in, 278
 community-based care in, 314
 community-based physical activity programs in, 90*b*
 cost-effectiveness of interventions in, 16, 353, 359–60
 diabetes in, 10, 213
 diet and nutrition in, 110
 heart failure in, 184
 ischemic heart disease in, 139, 141–42

- kidney disease in, 236, 240, 244
- obesity/overweight in, 118, 120–21, 124–25, 127, 130
- physical activity in, 14, 82, 87, 89, 92–93
- priority-setting for treatments in, 378–80, 382, 384
- quality of care in, 332, 342
- rheumatic heart disease in, 201
- stroke in, 163
- tobacco use in, 68
- breastfeeding, 44, 47
- bronchiectasis, 268–69, 276
- bronchodilators, 274
- Brouwer, Elizabeth, 349
- Bukhman, Gene, 191
- Bulgaria, ischemic heart disease in, 138
- Bull, Fiona, 79
- burden of disease
 - asthma, 263–65
 - Chagas disease, 203
 - chronic obstructive pulmonary disease (COPD), 263–67
 - chronic respiratory diseases, 263–69, 266–67*f*
 - congenital heart disease (CHD), 191–92
 - diabetes, 209–12, 377
 - dyslipidemia, 390
 - heart failure, 173–77, 175–76*t*, 176*f*
 - hypertension, 389–90
 - ischemic heart disease (IHD), 136–40, 137*m*, 138–39*f*
 - obesity/overweight, 117–18
 - peripheral artery disease (PAD), 256
 - physical activity and inactivity, 80–81*f*, 80–82
 - rheumatic heart disease (RHD), 197
 - stroke, 157–59
- Burney, Peter, 263
- C**
- CABG (coronary artery bypass graft), 143, 185
- calcium channel blockers, 163, 179, 333, 391–93
- Callender, T., 181*b*
- Cambodia
 - community-based care in, 320–21
 - diabetes in, 217
 - integrated care in, 294
 - kidney disease in, 239–40
- Cameroon
 - community-based care in, 306, 308–10
 - quality of care in, 343
 - tobacco use in, 68
- Canada
 - cost-effectiveness of interventions in, 358
 - ischemic heart disease in, 143–45
 - kidney disease in, 235, 237
 - obesity/overweight in, 126
 - physical activity in, 87, 92–93
- cancer, 210
- Capewell, Simon, 70, 101
- carbohydrates, 121–22
- cardiac resynchronization therapy (CRT), 141, 147, 180, 183–84, 186, 359
- cardiometabolic disease, 37–55. *See also specific conditions*
 - bisphenol A and, 44
 - breastfeeding and, 44, 47
 - childhood weight gain and growth, 47–48
 - BMI in adulthood, 43
 - BMI in childhood and adolescence, 42–43
 - height in childhood, 43
 - weight and BMI in infancy, 42
 - community-based care, 312–14, 316
 - cost-effectiveness of interventions, 361
 - developmental origins of health and disease, 39–40, 40*f*
 - adjustments, 45
 - confounding issues, 45
 - genetic effects, 45
 - measurement errors, 45
 - fuel-mediated teratogenesis and, 40–41
 - genetic effects, 45
 - gestational diabetes and, 40–41, 41*f*, 47
 - integrated care and, 296
 - interventions, 46–48
 - cost-effectiveness, 361
 - maternal obesity and, 40–41, 41*f*, 47
 - maternal smoking and, 44
 - micronutrient supplementation, 46–47
 - nutritional interventions in pregnancy, 46–47
 - physical activity and, 79, 81, 82–86, 87, 89, 91
 - phytoestrogens and, 44
 - polychlorinated biphenyls and, 44
 - public health implications, 48–49
 - risk factors, 37–39, 38*f*
- cardiomyopathy, 8, 27, 173–75, 183–84, 193
- cardiovascular, respiratory, and related disorders (CVRDs). *See also specific conditions*
 - framework for addressing, 9, 32–33, 33*f*
 - mortality and morbidity trends, 24–25, 24*t*, 25–26*f*, 26*t*
 - risk factors
 - adolescence determinants, 31–32
 - alcohol use, 30
 - dyslipidemia, 28
 - early childhood determinants, 9, 30–31
 - high blood pressure, 29
 - middle childhood determinants, 31–32

- modifiable, 28–30
 - nonmodifiable, 27–28
 - obesity/overweight, 29
 - physical inactivity, 29–30
 - reducing, 32
 - social and ecological determinants, 30–32, 33
 - tobacco use, 28
- cardiovascular disease (CVD). *See also* cardiovascular, respiratory, and related disorders (CVRDs); ischemic heart disease (IHD)
 - mortality rates, 4
 - tobacco use and, 57–78. *See also* tobacco use
 - CVD mortality rates and, 64
 - CVD outcomes and, 63–67, 64*b*, 64*f*
 - CVD pathophysiology and mechanisms, 58–62, 59–60*f*
 - CVD risk factors, 62–63
- carotid and cerebrovascular diseases, 65
- carotid endarterectomy, 165
- carotid stenosis surgery, 166
- catecholamines, 58–59, 61–62, 66
- Cawley, J., 109
- CCC (chronic Chagas cardiomyopathy), 202–4
- CD. *See* Chagas disease
- CDSS (clinical decision support system), 317–19, 343
- Cecchini, M., 110
- Centers for Disease Control and Prevention, 392
- Chagas disease (CD), 191, 202–4
 - burden of disease, 203
 - heart failure and, 173, 176
 - interventions, 203
 - cost-effectiveness, 203–4
 - natural history, 202–3
 - pathogenesis, 202–3
 - risk factors, 27
- Chan, Juliana, 209
- Chandrasekar, Eeshwar, 209
- CHD. *See* coronary heart disease
- Chen, Jie, 157
- children
 - asthma and, 263–64
 - BMI
 - in childhood and adolescence, 42–43
 - in infancy, 42
 - cardiometabolic disease and, 47–48
 - height in childhood, 43
 - mortality rates, 49, 110, 350, 353
 - obesity/overweight, 31–32, 44, 47, 125, 127–28, 354
 - weight gain and growth, 42–43, 47–48
- Chile
 - community-based care in, 314–15
 - ischemic heart disease in, 142
 - obesity/overweight in, 124–25
 - priority-setting for treatments in, 382, 384
- China
 - congenital heart disease in, 191, 194
 - cost-effectiveness of interventions in, 353–54, 360, 369–70, 372–73
 - diabetes in, 210, 213, 217
 - diet and nutrition in, 106, 110
 - health care costs in, 8
 - integrated care in, 289–91, 293, 295
 - ischemic heart disease in, 137, 140–42
 - kidney disease in, 236, 240, 243, 245
 - obesity/overweight in, 118, 120–22, 124–27, 129–30
 - peripheral artery disease in, 8–9
 - physical activity in, 12, 82
 - quality of care in, 335
 - stroke in, 157, 159, 162–64, 166–67
- cholesterol. *See also* dyslipidemia
 - cardiometabolic disease and, 46
 - community-based care and, 317
 - cost-effectiveness of interventions, 356–58
 - high-density lipoprotein (HDL), 29, 46, 61–62, 390, 396
 - integrated care and, 297
 - low-density lipoprotein (LDL), 28, 61–62, 85, 146, 163, 335–36, 340, 389–91, 394, 396
 - management of, 389–90, 397
 - physical activity and, 85
 - as risk factor, 28–30
 - tobacco use and, 61–62
- chronic bronchitis, 264, 268–69
- chronic Chagas cardiomyopathy (CCC), 202–4
- chronic kidney disease (CKD), 235, 239–45
 - diabetes and, 210–12, 214, 220
 - epidemiology of, 239
 - hypertension and, 9, 396
 - integrated care and, 288, 294
 - interventions, 241, 243–44*t*
 - cost-effectiveness, 13, 245–46, 360
 - renal replacement therapy, 245–46, 245*f*
 - screening, 245, 246*b*
 - pharmacological interventions, 242
 - policy implications, 246–47, 247*t*
 - prevalence, 240
 - priority-setting for treatments, 375, 383
 - tobacco use and, 64, 66–67
- chronic obstructive pulmonary disease (COPD)
 - burden of disease, 263–67
 - clinical course and management, 273–74, 277
 - community-based care and, 306–7
 - cost-effectiveness of interventions, 13, 359
 - diagnosis, 273
 - heart failure and, 175

- mortality and morbidity trends, 27–28
- pharmacological management, 274–75
- prevention, 269
- primary care centers and, 15
- risk factors, 263–67
- tobacco use and, 65
- chronic respiratory diseases, 263–86, 264*t*.
 - See also specific conditions*
 - asthma, 263–65
 - assessment, 271–72
 - barriers to care, 272–73
 - diagnosis, 271
 - pharmacological management, 272
 - bronchiectasis, 268–69, 276
 - burden of disease, 263–69, 266–67*f*
 - chronic airway obstruction and COPD, 265–66
 - clinical course and management, 273–74
 - diagnosis, 273
 - pharmacological management, 274–75
 - chronic bronchitis, 268–69
 - community-based care and, 305–6, 310
 - idiopathic low FVC, 266–68, 275
 - interventions
 - cost-effectiveness, 359
 - management, 271–76
 - primary prevention, 269, 269*b*
 - principles of care, 270, 270*b*
 - mortality and morbidity rates, 23–25, 27–29
 - restrictive lung disease and fibrosis, 268
 - diagnosis, 275
 - treatment, 275–76
 - risk factors, 31, 33
 - systems and organization of care, 276–78, 277*t*, 278*b*
 - tobacco use and, 66
- cigar and cigarette smoking. *See* tobacco use
- Civil Servant Medical Benefit Scheme (CSMBS, Thailand), 383
- CKD. *See* chronic kidney disease
- claudication, 64, 253–54, 256–58
- clinical decision support system (CDSS), 317–19, 343
- clinical interventions
 - community-based care and, 306
 - cost-effectiveness, 10, 355, 372
 - diabetes, 218
 - obesity, 129
- cognitive rehabilitation, 168
- collaborative care, 294, 297, 312–13
- Colombia
 - community-based physical activity programs in, 90*b*
 - physical activity in, 14, 87, 89, 92–93
 - priority-setting for treatments in, 378–82, 384
- community-based health care, 305–26
 - case studies, 317–22, 318–20*f*
 - rheumatic heart disease (RHD), 199
 - self-management, 312–16, 313*t*, 316*b*, 317*f*
 - cost-effectiveness, 315–16
 - education in, 314–15
 - target populations, 314
 - technology for, 315
 - theories of, 313–14
 - stroke, 164
 - task-shifting, 305–12, 307–9*t*, 311*b*
- congenital heart disease (CHD), 191–96
 - burden of disease, 191–92
 - categories of, 191, 192*t*
 - curative care and treatment, 15, 194–95
 - hypertension and, 390
 - interventions, 192–94
 - cost-effectiveness, 195–96
 - neonatal screening, 194
 - prenatal screening, 193–94, 193*t*
 - prevention, 192–93
 - screening, 193–94, 195–96
 - palliative care and treatment, 194–95
 - prevalence rate, 191
 - risk factors, 26, 192
 - treatment, 194–95
 - access to, 10, 15
 - cost-effectiveness, 195–96
- Congleton, T. M., 162
- Consortium for the Epidemic of Nephropathy in Central America and Mexico, 241*b*
- Consortium of Health-Orientated Research in Transitioning Societies, 42, 49
- Control of Blood Pressure and Risk Attenuation (COBRA), 314
- COPD. *See* chronic obstructive pulmonary disease
- Cornelson, L., 362*n*2
- coronary artery bypass graft (CABG), 143, 185
- Coronary Artery Risk Development in Young Adults Study, 85
- coronary heart disease (CHD). *See also* heart failure; ischemic heart disease
 - cardiometabolic disease and, 37, 40, 42–45, 48
 - community-based care, 312
 - cost-effectiveness of interventions, 354
 - diabetes and, 210–11, 214
 - diet and, 102–4
 - hypertension and, 389–90, 394–96
 - integrated care and, 288, 294
 - ischemic heart disease and, 137
 - physical activity and, 82–83, 83*f*, 86–87
 - quality of care and, 335, 341

- risk factors, 29
 - stroke and, 160, 163
 - tobacco use and, 64–70
 - coronary vasoconstriction, 58*b*
 - corticosteroids, 272, 274–75
 - cost
 - cardiometabolic disease interventions, 49
 - Chagas disease (CD) interventions, 203–4
 - chronic respiratory disease interventions, 270, 272, 277
 - community-based care, 306, 308–9, 314–16
 - congenital heart disease interventions, 194–95
 - diabetes interventions, 211–12, 214–15, 218–19, 224
 - health care, generally, 57, 65–66, 86–87, 109, 124, 140
 - heart failure interventions, 178, 180–81, 183–84
 - hypertension interventions, 397
 - indirect, 87, 140, 159, 195, 212, 321, 390
 - ischemic heart disease, 140, 143
 - kidney disease interventions, 235, 238, 244–47
 - obesity/overweight interventions, 124, 125, 127–31
 - peripheral artery disease interventions, 258
 - physical activity interventions, 86–87, 89, 91–92
 - prevention, 360–61
 - priority-setting for treatments and, 383–84
 - quality of care and, 343–44
 - rheumatic heart disease interventions, 201–2
 - stroke interventions, 166, 168
 - treatment, 9–17, 360–61
 - cost-effectiveness of interventions, 10–13, 11*b*
 - acute and hospital-based care, 359–60
 - Chagas disease, 203–4
 - cholesterol, 357
 - chronic kidney disease (CKD), 245–46
 - community-based care, 355–56
 - congenital heart disease (CHD), 195–96
 - diabetes, 217–19, 220*t*, 357
 - diet and nutrition, 109–11, 352–53
 - dyslipidemia, 397
 - extended cost-effectiveness analyses (ECEAs), 11, 16, 369–73
 - first-level hospital care, 357–59
 - heart failure, 183–84, 185*t*, 359
 - hypertension, 357, 370*t*, 371–72, 397
 - individual-level interventions, 355–60
 - acute and hospital-based care, 359–60
 - cholesterol, 357
 - community-based care, 355–56
 - diabetes, 357
 - first-level hospital care, 357–59
 - heart failure, 359
 - hypertension, 357, 370*t*, 371–72
 - ischemic heart disease, 359–60
 - kidney disease, 360
 - medication availability and adherence, 358–59
 - primary health center care, 356–57
 - respiratory conditions, 359
 - rheumatic heart disease, 357
 - screening, 355–56
 - ischemic heart disease, 145, 359–60
 - kidney disease, 238, 360
 - mass media policies, 353–55
 - medication availability and adherence, 358–59
 - obesity/overweight, 127–30, 128*t*, 130*t*
 - peripheral artery disease (PAD), 258–60
 - physical activity, 91–92, 354–55
 - population-level interventions, 350–55, 350*f*
 - diet and nutrition, 352–53
 - mass media policies, 353–55
 - physical activity, 354–55
 - regulatory policy, 353–55
 - salt consumption, 353–54, 370*t*, 371
 - tobacco use, 350–52, 351*t*, 370–71, 370*t*
 - trans fats consumption, 353–54
 - primary health center care, 356–57
 - ratios, 12, 92, 110, 130, 350, 352–53, 355
 - regulatory policy, 353–55
 - respiratory conditions, 359
 - rheumatic heart disease, 201–2, 357
 - salt consumption, 353–54, 370*t*, 371
 - screening, 355–56
 - self-management, 315–16
 - stroke, 165, 168
 - threshold for, 130, 355, 384
 - tobacco use, 350–52, 351*t*, 370–71, 370*t*
 - trans fats consumption, 353–54
 - counseling, dietary, 47, 86
 - Criqui, Michael H., 253
 - Critchley, J. A., 70
 - critical limb ischemia, 257–58
 - cyclophosphamide, 242
- D**
- D'Alessandro, A., 66
 - DALYs (disability-adjusted life-years)
 - Chagas disease and, 203–4
 - congenital heart disease and, 191–92
 - cost-effectiveness of interventions and, 11–12, 350–54, 358–59
 - diabetes and, 211–12
 - diet and, 104, 110
 - heart failure and, 184–85
 - hypertension and, 390
 - ischemic heart disease and, 135, 137, 139–40, 145
 - obesity/overweight and, 127–30

- physical activity and, 87
- priority-setting for treatments and, 375, 377, 383
- rheumatic heart disease and, 197
- risk factors and, 4, 25, 27–29
- stroke and, 157–58, 169
- death rates. *See* mortality rates
- dementia, 64–65, 82, 86
- Denmark
 - cardiometabolic disease in, 47
 - diabetes in, 215
 - diet and nutrition in, 108
 - integrated care in, 292–93
 - taxation of unhealthy foods and beverages in, 362n1
- depression
 - community-based care and, 315
 - diabetes and, 210, 212, 214, 217, 288, 295, 297
 - integrated care and, 287–88
 - physical activity and, 83, 86–87
 - risk factors, 30
 - stroke and, 158–59, 161, 167
- developmental origins of health and disease (DOHaD) for cardiometabolic disease, 39–40, 40f
 - adjustments, 45
 - confounding issues, 45
 - genetic effects, 45
 - interventions, 37, 39–40, 49
 - measurement errors, 45
- diabetes, 209–34
 - burden of disease, 209–12, 377
 - cancer and, 210
 - cardiometabolic disease and, 39, 42
 - chronic kidney disease (CKD) and, 210
 - community-based care, 314
 - complications of, 6, 12, 210–11, 215, 219
 - coronary heart disease (CHD) and, 210
 - depression and, 217, 288, 295, 297
 - diagnosis, 215–16
 - diet and, 104
 - disability and, 211–12
 - end-stage renal disease (ESRD) and, 210, 241–42
 - heart failure and, 210
 - HIV/AIDS and, 292–94, 293t
 - hypertension and, 9, 240, 308–9, 320–21, 331–32, 340, 343, 384, 392, 394, 396
 - integrated care and, 289–93
 - interventions, 9, 213–15, 217, 220
 - cost-effectiveness, 217–19, 220t, 356, 357
 - management, 144, 214–15, 216, 220, 308
 - prevention, 213–14, 216, 219
 - priorities, 221, 221–23t
 - screening, 213, 215, 219, 396
 - ischemic heart disease and, 136
 - knowledge gaps, 221, 223
 - management of, 144, 214–15, 216, 220, 308
 - maternal, 39, 48, 192
 - mental health and, 287–88
 - mortality and morbidity trends, 27, 211–12, 211t
 - obesity/overweight and, 122
 - physical activity and, 84–85, 84–85f
 - prevalence rate, 48, 63, 109, 209–10, 214, 216, 288–90, 292, 381
 - prevention, 12, 213, 216–18, 221, 223
 - priority-setting for treatments, 375, 377
 - quality of care and, 327
 - risk factors, 24–26
 - stroke and, 159–60, 210
 - tobacco use and, 63
 - treatment, 216–17
 - tuberculosis and, 288–92, 289f, 290–91t
- Diabetes Prevention Program (DPP), 84, 216, 222, 311
- diabetic retinopathy, 215, 220–21
- diagnosis
 - chronic obstructive pulmonary disease (COPD), 273
 - diabetes, 215–16
 - heart failure, 173
 - peripheral artery disease (PAD), 253–54
 - stroke, 162
- dialysis, 15, 64, 210, 235–40, 242–43, 375
- Diep, L., 83
- diet and nutrition, 101–15
 - carbohydrates, 121–22
 - cardiometabolic disease and, 39, 43, 46
 - chronic respiratory diseases and, 264, 267, 271
 - community-based care, 314
 - counseling, 47, 86
 - fatty acids, 14, 102, 104, 143, 353–54
 - folate deficiency, 192
 - grains, 102–4, 122, 124–25, 131
 - interventions, 105–9, 105t
 - cost-effectiveness, 109–11, 352–53
 - fiscal policies, 107, 107t
 - local food environment, 108
 - mass media campaigns, 105–7
 - multicomponent interventions, 109
 - organizational settings, 107–8
 - pregnancy and, 46–47
 - taxation of unhealthy beverages and foods, 108–9
 - trans fats restrictions, 108
 - micronutrients, 46–47, 121–22
 - obesity/overweight and, 117–18, 121–24, 127–28, 131
 - risk factors, 102–5, 103–4t
 - salt consumption, 16, 110, 163, 165, 353–54, 370t, 371–73

- stroke and, 160–61
 - sugar and sugar-sweetened beverages (SSBs), 11–13, 17, 102–9, 119, 123–28, 131, 222, 266, 352–53
 - trans fats consumption, 14, 102, 104, 106, 108, 353–54
 - vegetables, 13, 28, 32–33, 103–8, 124–26, 129, 131, 160–62, 169, 266
 - digital health strategies, 164–65
 - digoxin, 178–79, 186
 - Dirks, John, 235
 - disability
 - chronic respiratory diseases and, 276
 - community-based care and, 316–17
 - cost-effectiveness of interventions, 11, 16–17, 357
 - diabetes and, 211–12
 - heart failure and, 174, 184
 - integrated care and, 288
 - ischemic heart disease and, 135
 - primary care centers and, 3–4*b*
 - quality of care and, 328
 - risk factors, 25–28
 - stroke and, 157–58, 160–61, 166–67
 - diuretics, 6, 15, 163, 177, 181, 183–84, 186, 359, 391–93, 395
 - DOHaD. *See* developmental origins of health and disease
 - Doll, R., 64
 - DPP. *See* Diabetes Prevention Program
 - drugs. *See* pharmacological interventions
 - Dugani, Sagar B., 135
 - dyslipidemia
 - burden of disease, 390
 - cost-effectiveness of interventions, 397
 - interventions, 393–95
 - polypills, 395
 - screening, 396
 - statins, 394. *See also* statins
 - tobacco use and, 62
- E**
- East Asia and Pacific. *See also specific countries*
 - congenital heart disease in, 192
 - diabetes in, 220
 - heart failure in, 176, 185
 - ischemic heart disease in, 137–38, 141
 - kidney disease in, 245
 - peripheral artery disease in, 256
 - stroke in, 157
 - ECEAs (extended cost-effectiveness analyses), 11, 16, 369–73
 - echocardiography, 173, 178, 182, 184, 186, 194, 199, 201, 357, 396
 - Egypt, Arab Republic of
 - diabetes in, 210
 - priority-setting for treatments in, 378–79
 - tobacco use in, 68
 - e-Health, 164
 - ejection fraction, 177–78, 181–82
 - electronic nicotine delivery systems (electronic cigarettes), 69
 - El Nahas, Meguid, 235
 - El Salvador, kidney disease in, 241*b*
 - EMLs. *See* essential medicines lists
 - endothelial dysfunction, 58–62, 58*b*
 - endovascular therapy, 257–58
 - end-stage renal disease (ESRD), 235, 239–42
 - diabetes and, 210, 215, 219–20, 241–42
 - dialysis, 242
 - epidemiology of, 240
 - hypertension and, 241–42
 - interventions, 241–42
 - cost-effectiveness, 357, 371
 - prevalence, 240
 - priority-setting for treatments, 383
 - transplantation, 243–44
 - treatment, 242–45
 - Engelgau, Michael, 327
 - ESRD. *See* end-stage renal disease
 - essential medicines lists (EMLs), 375, 377–78
 - estimated glomerular filtration rate (eGFR), 239
 - Ethiopia
 - cost-effectiveness of interventions in, 370–71
 - hypertensive treatment in, 16, 371–72
 - rheumatic heart disease in, 197
 - Europe and Central Asia. *See also specific countries*
 - diabetes in, 211, 220
 - heart failure in, 174, 176, 185
 - ischemic heart disease in, 138–39
 - kidney disease in, 245
 - peripheral artery disease in, 256–57, 259
 - European Medicines Agency, 377
 - exercise. *See* physical activity
 - extended cost-effectiveness analyses (ECEAs), 11, 16, 369–73
- F**
- Fall, Caroline H. D., 37
 - fatty acids, 14, 102, 104, 143, 353–54
 - FCTC. *See* Framework Convention on Tobacco Control
 - Feigin, Valery, 157
 - Ferrante, D., 110
 - fibrinogen, 61–62, 67
 - fibrosis and restrictive lung disease, 268, 275–76
 - Figueira, F. R., 84
 - financial risk protection (FRP), 2, 9, 11, 16–17, 369–73

- Finland
 cardiometabolic disease in, 42–43, 45, 48
 diabetes in, 213, 216
 diet and nutrition in, 105, 109
 kidney disease in, 238
 physical activity in, 92–93
 taxation of unhealthy foods and
 beverages in, 362n1
 Finnish Diabetes Prevention Trial, 84
 fiscal policies, 13–14, 107, 350, 352
 folic acid, 46–47, 166, 192
 food advertising and labeling, 105, 123, 124–25,
 129–31
 Food and Drug Administration (U.S.), 274
 Football Fans in Training program, 91
 forced vital capacity (FVC), 265–68, 275
 Forouhi, N. G., 290
 Forsdahl, A., 37
 Fowkes, F. Gerald R., 253
 Framework Convention on Tobacco
 Control (FCTC), 9, 32, 70, 144
 Framingham Heart study, 23, 165
 France
 diet and nutrition in, 107–8
 ischemic heart disease in, 137
 obesity/overweight in, 125
 priority-setting for treatments in, 382
 taxation of unhealthy foods and
 beverages in, 362n1
 Freeman, S. D., 162
 free trade agreements, 119
 Freinkel, N., 40
 Friends of Aldo Castenada Foundation, 196
 Frisvold, D., 109
 FRP. *See* financial risk protection
 fuel-mediated teratogenesis, 40–41
 FVC (forced vital capacity), 265–68, 275
- G**
- The Gambia, nutrition during pregnancy in, 46
 Garrett, S., 92
 Gaziano, Thomas A., 1, 135, 349, 389
 GDM. *See* gestational diabetes mellitus
 gender issues
 physical activity, 80, 91*b*
 tobacco use, 65
 generic medications, 8, 17, 145–46, 358
 genetics
 developmental origins of health and disease
 (DOHaD), 45
 obesity/overweight, 123
 tobacco use and, 62
 George, J., 238
 gestational diabetes
 cardiometabolic disease and, 40–41, 41*f*, 47
 congenital heart disease and, 196
 defined, 209
 screening for, 217, 396
 GFR (glomerular filtration rate), 239, 243–44
 Glassman, Amanda, 375
 Global Advocacy for Physical Activity Initiative, 88
 Global Burden of Disease (GBD) Study, 102, 135, 174.
See also burden of disease
 Global Initiative for Asthma (GINA), 270–73
 Global Initiative for Chronic Obstructive Lung Disease
 (GOLD), 265
 Global Physical Activity Questionnaire (GPAQ), 81
 Global Registry of Acute Coronary Events, 142
 Global Strategy on Diet, Physical Activity and Health
 (WHO), 92, 107
 glomerular filtration rate (GFR), 239, 243–44
 Goenka, Shifalika, 79
 GOLD (Global Initiative for Chronic Obstructive Lung
 Disease), 265
 GPAQ (Global Physical Activity Questionnaire), 81
 grains, 102–4, 122, 124–25, 131
 Green, R., 362n2
 Guatemala
 cardiometabolic disease in, 46
 community-based care in, 310
 cost-effectiveness of interventions in, 356
 hypertension in, 397
 Gulf Registry of Acute Coronary Events, 142, 143
 Gupta, Rajeev, 389
- H**
- Harikrishnan, S., 181*b*
 Hasan, Babar, 191
 Hawkesworth, S., 46
 HCV (hepatitis C virus), 293
 HDL. *See* high-density lipoprotein
 health care costs. *See also* cost
 diet and nutrition, 109
 ischemic heart disease in, 140
 obesity/overweight, 124
 physical activity and, 86–87
 tobacco use and, 57, 65–66
 health care providers
 community-based care and, 305, 307, 313–14, 316
 integrated care and, 297
 ischemic heart disease and, 136, 145
 obesity/overweight and, 130–31
 physical activity and, 88
 quality of care and, 328, 334–35, 342
 rheumatic heart disease and, 200
 stroke and, 162, 164, 166–67

- health technology assessment (HTA), 369, 375, 384, 386
- heart disease. *See* congenital heart disease; coronary heart disease; ischemic heart disease
- heart failure, 173–90
- burden of disease, 173–77, 175–76*t*, 176*f*
 - causes, 173
 - diabetes and, 210
 - diagnosis, 173
 - health service arrangements, 180–82
 - interventions, 177–80, 183*t*
 - angiotensin-converting enzyme (ACE) inhibitors, 178, 184
 - angiotensin receptor blockers, 178
 - anticoagulants, 179
 - beta blockers, 177–78, 184
 - case management, 180
 - cost-effectiveness, 183–84, 185*t*, 359
 - devices, 180, 184
 - digoxin, 178–79
 - diuretics, 177, 183–84
 - exercise-based rehabilitation, 179–80
 - inotropes, 179
 - mineralocorticoid receptor antagonists, 178, 184
 - noninvasive positive pressure ventilation, 179
 - pharmacological, 177–79
 - mortality rates, 174, 175*t*
 - prevalence rates, 174, 176*t*
 - stages and classes of, 174*b*
 - tobacco use and, 58, 62, 64–65, 68, 70
- hemodialysis, 15, 239, 245–46, 383–84
- hemorrhagic stroke, 15, 30, 65, 83, 159–61, 165, 169
- Henry Ford Exercise Testing Project, 85
- hepatitis C virus (HCV), 293
- Hersch, Fred, 305
- HHE (home health education), 315, 343
- high blood pressure. *See* hypertension
- high-density lipoprotein (HDL), 29, 46, 61–62, 390, 396
- high-income countries (HICs)
- cardiometabolic disease in, 39, 41–42, 44
 - cardiovascular, respiratory, and related disorders (CVRDs) in, 24–26, 30
 - Chagas disease in, 203–4
 - chronic respiratory diseases in, 269–71
 - community-based care in, 311
 - congenital heart disease in, 191–95
 - cost-effectiveness of interventions in, 12, 14–15, 349–50, 354–55
 - diabetes in, 213–15, 217–20
 - heart failure in, 173–74, 183–84
 - hypertension in, 389–90
 - integrated care in, 292
 - ischemic heart disease in, 135–37, 143–45
 - obesity/overweight in, 117, 119–21
 - peripheral artery disease in, 253–58
 - physical activity in, 80, 86–89
 - quality of care in, 341–42, 344–45
 - stroke in, 157, 162–63, 168–69
- HITAP (Health Intervention and Technology Assessment Program), 384
- HIV/AIDS
- chronic respiratory diseases and, 269, 278
 - community-based care, 306
 - diabetes and, 217, 223, 292–94, 293*t*
 - integrated care and, 287, 290, 292–94
 - ischemic heart disease (IHD) and, 135–36
 - kidney disease and, 236, 240
 - priority-setting for treatments, 384
 - quality of care and, 331
- home health education (HHE), 315, 343
- homocysteine-lowering therapy, 166
- Howard, K., 245
- HTA (health technology assessment), 369, 375, 384, 386
- Hu, Frank B., 117
- Huffman, Mark D., 173, 203
- Hungary
- diet and nutrition in, 108
 - taxation of unhealthy foods and beverages in, 362*n*1
- hypercholesterolemia, 390. *See also* dyslipidemia
- hypersensitivity pneumonitis, 264, 268, 275–76
- hypertension, 389–404
- burden of disease, 389–90
 - diabetes and, 9, 240, 308–9, 320–21, 331–32, 340, 343, 384, 394
 - end-stage renal disease (ESRD) and, 241–42
 - interventions, 9, 390–93, 392–93*t*, 393*f*, 398*b*
 - antiplatelet therapy, 393
 - combination therapy, 393
 - cost-effectiveness, 357, 370*t*, 371–72, 397
 - pharmacological, 391
 - screening, 395–96
 - tobacco use and, 62–63
 - treatment, 330, 370, 372
- I**
- ICDs. *See* implantable cardioverter defibrillators
- ICERs. *See* incremental cost-effectiveness ratios
- IDF. *See* International Diabetes Federation
- idiopathic low FVC, 266–68, 275
- idiopathic pulmonary fibrosis (IPF), 268, 275–76
- IHD. *See* ischemic heart disease
- IMAI (Integrated Management of Adolescent and Adult Health), 277

- impaired glucose tolerance (IGT), 37, 41, 84–85, 109, 210, 214, 315
- implantable cardioverter defibrillators (ICDs), 15, 141, 147, 180, 183–84, 359
- incremental cost-effectiveness ratios (ICERs)
 - Chagas disease, 204
 - community-based care, 315–16, 356
 - congenital heart disease, 195
 - diabetes, 217, 219–20
 - heart failure, 179, 184–85, 359
 - ischemic heart disease (IHD), 141, 143, 145, 147, 360
 - kidney disease, 245
 - rheumatic heart disease, 201–2
- India
 - cardiometabolic disease in, 39, 41–42
 - community-based care in, 308–10, 317
 - congenital heart disease in, 194, 196
 - cost-effectiveness of interventions in, 11–12, 351–53
 - diabetes in, 213, 216–18
 - health care costs in, 8
 - heart failure in, 181, 181*b*
 - hypertension in, 389
 - integrated care in, 289–90
 - kidney disease in, 244
 - obesity/overweight in, 121, 124, 126–27, 129–30
 - physical activity in, 80, 82
 - priority-setting for treatments in, 382
 - quality of care in, 329, 334–35
 - rheumatic heart disease in, 200–202
 - stroke in, 167–68
 - tobacco use in, 57
- Indonesia
 - integrated care in, 291
 - priority-setting for treatments in, 378–80, 382
- infectious diseases. *See also specific diseases*
 - chronic respiratory diseases and, 269
 - community-based care, 306
 - congenital heart disease and, 196
 - cost-effectiveness of interventions, 373
 - diabetes and, 210, 212, 223
 - integrated care and, 288–89
 - kidney disease and, 237, 240
- inflammation of vascular tissue, 58*b*, 61–62
- Inglis, S. C., 180
- inhaled corticosteroids, 7, 9, 12, 15, 271–72, 274, 359
- in-hospital mortality
 - heart failure, 179–81
 - ischemic heart disease, 143
 - kidney disease, 235–36
 - quality of care and, 329
- inotropes, 179
- insulin
 - cardiometabolic disease and, 39, 43, 46–47
 - cost-effectiveness of, 12
 - diabetes treatment, 212, 214, 218, 222
 - integrated care and, 292
 - obesity/overweight and, 122
 - priority-setting processes and, 375, 377–79
 - tobacco use and, 61, 63
- insulin resistance
 - cardiometabolic disease and, 39, 41, 43, 45–46
 - obesity/overweight and, 118
 - physical activity and, 86
 - tobacco use and, 59–61, 63
- integrated care, 287–97, 294–95*t*, 295*f*, 298*t*
 - adherence to treatment and, 296–97
 - blood pressure (BP) and, 295, 297
 - body mass index (BMI) and, 292
 - cardiometabolic disease and, 296
 - cholesterol and, 297
 - chronic kidney disease (CKD) and, 288, 294
 - chronic respiratory diseases, 277–78
 - coronary heart disease (CHD) and, 288, 294
 - depression and, 287–88
 - diabetes and, 289–93
 - disability and, 288
 - health care providers and, 297
 - HIV/AIDS and, 287, 290, 292–94
 - infectious diseases and, 288–89
 - insulin and, 292
 - kidney disease and, 294
 - obesity/overweight and, 292
 - physical activity and, 288
 - primary care centers and, 295, 297
 - relative risk (RR) and, 292–93
 - risk factors and, 287–88, 292
 - self-management interventions, 295
 - tuberculosis and, 287–92, 294
- Integrated Management of Adolescent and Adult Health (IMAI), 277
- INTERHEART study, 28, 65, 67, 68
- intermittent claudication, 256–57
- International Agency for Research on Cancer, 144
- International Charter on Cardiovascular Prevention and Rehabilitation, 147
- International Diabetes Federation (IDF), 27, 209–12, 214–15, 288, 290, 320, 378
- International Physical Activity Questionnaire, 81
- International Society of Nephrology, 237*b*
- International Society of Peritoneal Dialysis, 239
- International Study of Asthma and Allergies in Childhood, 264

International Union Against Tuberculosis and Lung Disease, 289

INTERSTROKE study, 28, 65, 159

interventions

- cardiometabolic disease, 46–48
- Chagas disease, 203
- chronic kidney disease (CKD), 241, 243–44*t*
 - cost-effectiveness, 245–46
 - renal replacement therapy, 245–46, 245*f*
 - screening, 245, 246*b*
- chronic respiratory diseases
 - management, 271–76
 - primary prevention, 269, 269*b*
 - principles of care, 270, 270*b*
- congenital heart disease (CHD), 192–94
 - cost-effectiveness, 195–96
 - neonatal screening, 194
 - prenatal screening, 193–94, 193*t*
 - prevention, 192–93
 - screening, 193–94, 195–96
- diabetes, 9, 213–15, 217, 220
 - cost-effectiveness, 217–19, 220*t*, 357
 - management, 214–15
 - prevention, 213–14, 216, 219
 - priorities, 221, 221–23*t*
 - screening, 213, 215, 219, 396
- diet and nutrition, 105–9, 105*t*
 - cost-effectiveness, 109–11, 352–53
 - fiscal policies, 107, 107*t*
 - local food environment, 108
 - mass media campaigns, 105–7
 - multicomponent interventions, 109
 - organizational settings, 107–8
 - taxation of unhealthy beverages and foods, 108–9
 - trans fats restrictions, 108
- dyslipidemia, 393–95
 - cost-effectiveness, 397
 - polypills, 395
 - screening, 396
 - statins, 394
- end-stage renal disease (ESRD), 241–42
- essential package, 6–7*t*, 15–16
- heart failure, 177–80, 183*t*
 - angiotensin-converting enzyme (ACE) inhibitors, 178, 184
 - angiotensin receptor blockers, 178
 - anticoagulants, 179
 - beta blockers, 177–78, 184
 - case management, 180
 - cost-effectiveness, 183–84, 185*t*, 359
 - devices, 180, 184
 - digoxin, 178–79
 - diuretics, 177, 183–84
 - exercise-based rehabilitation, 179–80
 - inotropes, 179
 - mineralocorticoid receptor antagonists, 178, 184
 - noninvasive positive pressure ventilation, 179
 - pharmacological, 177–79
- hypertension, 9, 390–93, 392–93*t*, 393*f*, 398*b*
 - antiplatelet therapy, 393
 - combination therapy, 393
 - cost-effectiveness, 357, 370*t*, 371–72, 397
 - pharmacological, 391
 - screening, 395–96
- ischemic heart disease (IHD), 140–47, 141–42*t*
 - access to medications, 145–46
 - acute management, 140, 142–43, 147
 - cardiac rehabilitation, 147
 - cardiac resynchronization therapy, 147
 - cost-effectiveness, 145, 359–60
 - implantable cardioverter defibrillators, 147
 - individual-level, 144–45
 - population-level, 144
 - secondary prevention, 143–46
- kidney disease, 237
 - cost-effectiveness, 238, 360
- mental health, 296–97
- obesity/overweight, 123–27, 131*t*
 - agricultural policies, 124
 - bariatric surgery, 127
 - cost-effectiveness, 127–30, 128*t*, 130*t*
 - food advertising, 125
 - food labeling, 124–25
 - mass media campaigns, 125
 - nutritional policies, 124
 - pharmacological strategies, 126–27
 - prevention, 117, 122–24, 130–31
 - school-based interventions, 125–26
 - urban planning and design, 126
 - weight-loss diets, 126
 - workplace interventions, 125–26
- patient-provider-level interventions, 332–43, 333*t*, 334*f*, 335*b*, 336–40*t*, 341*f*, 342*b*
 - acute phase, 332–34
 - chronic phase, 334–43
 - mobile communication technology and, 341, 342*b*
 - task-shifting, 341, 343
- peripheral artery disease (PAD), 256–58
 - cost-effectiveness, 258–60
 - critical limb ischemia, 257–58
 - intermittent claudication, 256–57
- physical activity, 87–91
 - community-based programs, 90*b*, 91
 - cost-effectiveness, 91–92, 354–55

- primary health care, 88–89
 - public education campaigns, 89
 - sports systems and programs, 89, 91
 - transport and urban design, 89
 - whole-of-school programs, 88
 - prevention, 13–14
 - restrictive lung disease and fibrosis, 275–76
 - rheumatic heart disease (RHD), 197–201, 198*t*
 - cardiac surgery, 198–99
 - community-based programs, 199
 - cost-effectiveness, 201–2, 357
 - echocardiography, 199
 - primary prevention, 197
 - primordial prevention, 199
 - public policy, 200, 200*t*
 - secondary prevention, 198, 201
 - surgical care platforms, 199–200
 - system-level interventions, 328–31, 329–30*t*, 331–32*b*
 - acute phase, 328–29
 - chronic phase, 329–31
 - IPF. *See* idiopathic pulmonary fibrosis
 - Iran
 - kidney disease in, 244
 - obesity/overweight in, 125
 - quality of care in, 337, 339
 - stroke in, 161, 168
 - tobacco use in, 68
 - Irlam, J., 201
 - ischemic heart disease (IHD), 135–56
 - burden of disease, 136–40, 137*m*, 138–39*f*
 - cardiometabolic disease and, 38
 - heart failure and, 173–77, 179, 181, 184–85
 - HIV/AIDS and, 136
 - hypertension and, 389–90, 395, 397
 - interventions, 140–47, 141–42*t*
 - access to medications, 145–46
 - acute management, 140, 142–43, 147
 - cardiac rehabilitation, 147
 - cardiac resynchronization therapy, 147
 - cost-effectiveness, 12, 145, 356–58, 359–60, 371–72
 - implantable cardioverter defibrillators, 147
 - individual-level, 144–45
 - population-level, 144
 - secondary prevention, 143–46
 - manifestations of, 136
 - medications
 - access to, 145–46
 - adherence, 146–47
 - mortality and morbidity trends, 26, 27*f*
 - risk factors, 136
 - tobacco use and, 67–68, 144
 - ischemic stroke, 159–62
 - community-based care, 316
 - hypertension and, 390, 396
 - mortality and morbidity rates, 27
 - primary care centers and, 15
 - risk factors, 30
 - tobacco use and, 65
 - treatment, 165–66
- J**
- Jabbour, Samer, 57
 - Janssen, I., 87
 - Japan
 - Chagas disease in, 203
 - diabetes in, 213
 - diet and nutrition in, 106
 - ischemic heart disease in, 137
 - obesity/overweight in, 126
 - stroke in, 165
 - tobacco use in, 67
 - Jarvis, Deborah, 263
 - Jeemon, Panniyammakal, 327, 389
 - Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 163
 - Joseph, K. S., 48
 - Joshi, Rohina, 305
- K**
- Kamano, Jemima H., 327
 - Katzmarzyk, P. T., 87
 - Kengne, Andre Pascal, 305
 - Khatibzadeh, S., 177
 - kidney disease, 235–52. *See also* chronic kidney disease (CKD); end-stage renal disease (ESRD)
 - etiology, 236–37
 - hypertension and, 393
 - integrated care and, 294
 - interventions, 237
 - cost-effectiveness, 238, 360
 - mortality and morbidity rates, 24–26, 236, 236*t*
 - policy implications, 238–39, 238–39*t*
 - prevalence, 235–36
 - priority-setting for treatments, 383–86, 383*b*, 385*b*
 - tobacco use and, 63–64
 - Kidney Help Trust of Chennai, 246*b*
 - Korea, Republic of
 - diet and nutrition in, 106
 - ischemic heart disease in, 137
 - obesity/overweight in, 125
 - priority-setting for treatments in, 384
 - Kramer, M., 48
 - Kudesia, Preeti, 327

- Kumar, R. Krishna, 191
 Kumaran, Kalyanaraman, 37
 Kwan, G. F., 183
 Kyrgyz Republic
 diabetes in, 212
 priority-setting for treatments in, 380
- L**
- LABAs (long-acting beta2-agonists), 272, 274
 Laine, J., 92
 La Isla Foundation, 241*b*
 Lambert, Vicki, 79
 Latin America and Caribbean.
 See also specific countries
 Chagas disease in, 203–4
 community-based care in, 310
 cost-effectiveness of interventions in, 353, 358
 diabetes in, 211–12, 216, 220
 diet and nutrition in, 110
 heart failure in, 176, 185
 ischemic heart disease in, 138–40, 142–43
 kidney disease in, 236, 244–45
 peripheral artery disease in, 257, 259–60
 physical activity in, 88
 priority-setting for treatments in, 376
 rheumatic heart disease in, 200
 stroke in, 157
 LDL. *See* low-density lipoprotein
 Lee, Edward S., 327
 leukotriene receptor antagonists, 272
 Levin, Carol, 349
 Levy, D., 67
 Li, Chaoyun, 157
 LICs. *See* low-income countries
 Lifestyle in Pregnancy and Offspring study, 47
 life years (LYs)
 cost-effectiveness of interventions and, 11, 350, 352, 354
 diabetes and, 211
 diet and, 103–4
 hypertension and, 390
 ischemic heart disease and, 135, 137
 obesity/overweight and, 127
 physical activity and, 87
 priority-setting for treatments and, 375
 stroke and, 157
 lipids. *See also* cholesterol; dyslipidemia
 diabetes and, 214
 hypertension and, 394–96
 interventions, 166
 oxidation and tobacco use, 61
 stroke and, 164
 LMICs. *See* low- and middle-income countries
 London Stroke Carers Training Course (LSCTC), 167
 long-acting beta2-agonists (LABAs), 272, 274
 Look AHEAD study, 218
 low- and middle-income countries (LMICs)
 cardiometabolic disease in, 39, 41–44
 cardiovascular, respiratory, and related disorders (CVRDs) in, 23–30, 32–33
 Chagas disease in, 202–4
 chronic respiratory diseases in, 263–64, 271–72, 276–77
 community-based care in, 305–6, 310–17
 congenital heart disease in, 191–96
 cost-effectiveness of interventions in, 12–14, 349–51, 353
 diabetes in, 209–10, 212–13, 215–16, 218–21, 223–24
 diet and nutrition in, 108, 110
 heart failure in, 179–81, 181*b*, 183–84
 integrated care in, 288–90, 294–97
 ischemic heart disease in, 135–37
 obesity/overweight in, 118–22, 124–27
 peripheral artery disease in, 253–54, 256, 258, 260
 physical activity in, 87–89
 primary care centers in, 16–17
 priority-setting for treatments in, 375–78
 quality of care in, 341–43
 rheumatic heart disease in, 197–202
 stroke in, 157–59, 161–69
 low birth weight
 cardiometabolic disease in, 37, 39, 43–45
 chronic respiratory diseases and, 267–68
 kidney disease and, 241
 as risk factor, 30–31
 low-density lipoprotein (LDL)
 ischemic heart disease and, 146
 management of, 389–91, 394, 396
 physical activity and, 85
 quality of care and, 335–36, 340
 as risk factor, 28
 stroke and, 163
 tobacco use and, 61–62
 low-income countries (LICs)
 cardiovascular, respiratory, and related disorders (CVRDs) in, 24–26, 28–30
 cost-effectiveness of interventions in, 9–10, 13, 356, 373
 diet and nutrition in, 107
 ischemic heart disease in, 139, 141–42, 146
 kidney disease in, 236
 primary care centers in, 16
 quality of care in, 341, 345
 rheumatic heart disease in, 201
 stroke in, 169

- Lubinga, S. J., 202
 Luo, Rong, 157
 LYs. *See* life years
- M**
- Magee, Matthew, 287
 Malawi
 chronic respiratory diseases in, 278
 integrated care in, 294
 Malaysia
 ischemic heart disease in, 143
 priority-setting for treatments in, 384
 quality of care in, 342
 Malik, Vasanti S., 117
 Marin-Neto, J. Antonio, 191
 Marks, Guy, 263
 mass media campaigns
 cost-effectiveness of interventions and, 350–53, 360
 diet and nutrition, 105–7
 ischemic heart disease, 144
 obesity/overweight, 124–25, 129–31
 physical activity, 89
 stroke, 162
 Maternal and Infant Nutrition Interventions in Matlab (MINIMat), 46, 47
 maternal obesity, 40–41, 41*f*, 47
 maternal tobacco use, 44
 Mauritius
 diabetes in, 210
 diet and nutrition in, 106, 109
 ischemic heart disease in, 144
 Mayosi, Bongani, 191
 Mbanya, Jean-Claude, 1, 209
 McGuire, Helen, 305
 medication. *See* adherence to treatment; pharmacological interventions
 mental health
 depression, 30, 83, 86–87, 158–59, 161, 167, 210, 212, 214, 217, 287–88, 315
 diabetes and, 287–88
 interventions, 296–97
 metformin, 218
 Mexico
 chronic respiratory diseases in, 278
 community-based care in, 310, 315
 cost-effectiveness of interventions in, 10–12, 351, 353, 356
 diabetes in, 218
 diet and nutrition in, 108, 110
 hypertension in, 397
 integrated care in, 291
 kidney disease in, 241–43, 245–46
 obesity/overweight in, 119–20, 124–25, 127, 130
 priority-setting for treatments in, 378–80
 quality of care in, 330, 337, 342
 stroke in, 163
 taxation of unhealthy foods and beverages in, 12, 362*n*1
 tobacco use in, 68
 Micha, Renata, 101
 micronutrients, 46–47, 121–22
 MICs. *See* low- and middle-income countries; middle-income countries
 Middle East and North Africa. *See also specific countries*
 congenital heart disease in, 192
 cost-effectiveness of interventions in, 358
 diabetes in, 210–11, 220
 heart failure in, 185
 ischemic heart disease in, 138–39, 142–43, 146
 kidney disease in, 244–45
 peripheral artery disease in, 257, 259–60
 physical activity in, 81, 92
 middle-income countries (MICs). *See also* low- and middle-income countries
 cardiovascular, respiratory, and related disorders (CVRDs) in, 23–29
 chronic respiratory diseases in, 263–64
 congenital heart disease in, 196, 198
 cost-effectiveness of interventions in, 9–13, 352–53, 371
 diet and nutrition in, 108, 110
 heart failure in, 181
 ischemic heart disease in, 139, 141–43
 kidney disease in, 236
 peripheral artery disease in, 255–56
 physical activity in, 80
 primary care centers in, 15, 16
 priority-setting for treatments in, 377
 quality of care in, 334–35, 345
 stroke in, 168–69
 mineralocorticoid receptor antagonists, 178, 184
 Miranda, J. Jaime, 157
 mitral regurgitation, 147
 mobile communication technology, 341, 342*b*
 Model List of Essential Medicines (WHO), 9, 14, 145, 147, 177
 Montoya, Pablo Aschner, 209
 MoPoTsyo Model of Care (Cambodia), 320–22
 Moran, Andrew E., 67, 135, 327
 morbidity rates
 asthma, 27
 cardiovascular, respiratory, and related disorders (CVRDs), 24–25, 24*t*, 25–26*f*, 26*t*
 chronic obstructive pulmonary disease (COPD), 27

chronic respiratory diseases, 23–25, 27–29
 diabetes, 27, 211–12, 211*t*
 ischemic heart disease (IHD), 26, 27*f*
 ischemic stroke, 27
 kidney disease, 24–26
 peripheral artery disease (PAD), 26–27, 256,
 257–58*f*, 259–60*f*
 stroke, 26, 27*f*, 157, 158*m*, 160, 162, 211, 389
 Morocco, priority-setting for treatments in, 378–81
 mortality rates, 4–8, 8*f*
 asthma, 27
 cardiovascular, respiratory, and related disorders
 (CVRDs), 24–25, 24*t*, 25–26*f*, 26*t*, 30
 cardiovascular disease, 4, 64
 children, 49, 110, 350, 353
 chronic obstructive pulmonary disease (COPD),
 27–28
 chronic respiratory diseases, 23–25, 27–29
 diabetes, 27, 211–12, 211*t*
 heart failure, 174, 175*t*
 ischemic heart disease, 26, 27*f*, 138, 140, 144
 ischemic stroke, 27
 kidney disease, 24–26, 236, 236*t*, 244
 peripheral artery disease, 26–27, 256–58, 257–60*f*
 premature mortality, 25, 57, 82, 87, 211, 305
 rheumatic heart disease, 197
 stroke, 26, 27*f*, 157, 158*m*, 160, 162, 168, 211, 389
 movement therapy, 168
 Mozaffarian, Dariush, 101
 Multicenter Automated Defibrillator Implantation
 Trial, 66
 multicomponent interventions
 diabetes, 217
 diet and nutrition, 105, 109
 obesity, 125
 quality of care, 329
 Murray, C. J., 110
 mycophenolate mofetil, 242
 myocardial infarction, 136
 myocardial ischemia, 58*b*
 myocarditis, 8, 27, 173–75

N

NAFTA (North American Free Trade Agreement), 119
 Naicker, Saraladevi, 235
 Naidoo, Nadraj G., 253
 Narayan, K. M. Venkat, 209, 287
 National Autonomous University of Nicaragua at
 León, 241*b*
 national essential medicines lists (NEMLS), 375,
 377–79, 381–83, 386
 National Health and Nutrition
 Examination Survey, 67

National Health Security Office (NHSO, Thailand),
 383–84
 National Institutes of Health (NIH), 162
 National Kidney Foundation, 241
 NEMLS. *See* national essential medicines lists
 Nepal, cardiometabolic disease in, 46
 nephropathy, 27
 neuropathy, 27, 219
 Neutral Protamine Hagedorn (NPH) insulin, 377, 379
 New York Heart Association, 174*b*
 New Zealand
 diet and nutrition in, 106–7
 obesity/overweight in, 126
 physical activity in, 87–88
 stroke in, 164
 Ng, S. W., 82
 Nicaragua, kidney disease in, 241*b*
 nicotine, 28, 58, 60–63, 66, 68–69, 254.
See also tobacco use
 nicotine replacement therapy (NRT), 144–45, 271, 351
 Nigeria
 diabetes in, 218
 kidney disease in, 240, 242
 quality of care in, 343
 stroke in, 161
 Nikolic, Irina, 349
 noninvasive positive pressure ventilation, 179
 North American Free Trade Agreement (NAFTA), 119
 Norway
 diet and nutrition in, 108
 taxation of unhealthy foods and beverages in, 362*n*1
 NRT (nicotine replacement therapy), 144–45,
 271, 351
 Nugent, Rachel, 1, 349, 369
 nutrition. *See* diet and nutrition

O

obesity/overweight, 117–34
 behavioral change and, 121
 burden of, 117–18
 cardiometabolic disease and, 40–41, 41*f*,
 43–44, 47, 48
 cardiovascular, respiratory, and related disorders
 (CVRDs) and, 29–31
 children, 127–28
 chronic respiratory diseases and, 264
 community-based care, 312
 congenital heart disease and, 193–94
 diabetes and, 209, 213–14
 diet and, 102, 109, 121–23
 genetic factors, 123
 income status and, 119–20
 integrated care and, 292

- interventions, 123–27, 131*t*
 - agricultural policies, 124
 - bariatric surgery, 127
 - cost-effectiveness, 12–13, 127–30, 128*t*, 130*t*, 350, 352–54
 - food advertising, 125
 - food labeling, 124–25
 - mass media campaigns, 125
 - nutritional policies, 124
 - pharmacological strategies, 126–27
 - prevention, 117, 122–24, 130–31
 - school-based interventions, 125–26
 - urban planning and design, 126
 - weight-loss diets, 126
 - workplace interventions, 125–26
 - ischemic heart disease and, 136, 144
 - maternal, 40–41
 - physical activity and, 79, 83, 85–86, 120–21
 - prevalence, 41, 118–19, 122–23, 315, 353
 - risk factors, 118–23, 119*f*
 - sociocultural norms and, 121
 - socioeconomic status and, 119–20
 - stroke and, 160–61, 169
 - trade liberalization and, 119
 - urbanization and, 120
 - occupational therapy, 168
 - Oceania
 - hypertension in, 390
 - ischemic heart disease in, 137
 - peripheral artery disease in, 256, 260
 - O'Donnell, Martin, 157
 - Olasky, S. J., 67
 - Onen, Churchill, 389
 - Organisation for Economic Co-operation and Development (OECD), 13, 127, 129–30, 130*t*
 - organ transplantation, 243–44
 - Ortegon, M., 110
 - Osmond, Clive, 37
 - oxidative stress, 58*b*
- P**
- PAD. *See* peripheral artery disease
 - Pakistan
 - community-based care in, 314–15
 - cost-effectiveness of interventions in, 12
 - diet and nutrition in, 106
 - integrated care in, 290
 - ischemic heart disease in, 140
 - kidney disease in, 244
 - priority-setting for treatments in, 378–80
 - palliative care and treatment, 194–95
 - passive smoking, 28
 - Patel, Anushka, 86, 305
 - PATH (Program for Appropriate Technology in Health), 320
 - patient-provider-level interventions
 - acute phase, 332–34
 - chronic phase, 334–43
 - mobile communication technology and, 341, 342*b*
 - quality of care, 332–43, 333*t*, 334*f*, 335*b*, 336–40*t*, 341*f*, 342*b*
 - task-shifting, 341, 343
 - PD. *See* peritoneal dialysis
 - Pedersen, J., 40
 - percutaneous coronary interventions (PCI), 12, 141, 143, 147, 360
 - Perez-Padilla, Rogelio, 263
 - peripheral artery disease (PAD), 253–62
 - burden of disease, 256
 - causes, 253–54
 - diagnosis, 253–54
 - epidemiology, 254
 - hypertension and, 390
 - interventions, 256–58
 - cost-effectiveness, 258–60
 - critical limb ischemia, 257–58
 - intermittent claudication, 256–57
 - ischemic heart disease and, 136
 - mortality and morbidity trends, 24, 26–27, 256, 257–58*f*, 259–60*f*
 - prevalence, 254, 255–56*f*
 - risk factors, 253, 254, 256, 260
 - tobacco use and, 64, 66
 - peritoneal dialysis (PD), 15, 236–39, 237*b*, 242, 383–86
 - Peru
 - obesity/overweight in, 125
 - priority-setting for treatments in, 378–80
 - pharmacological interventions
 - chronic kidney disease (CKD), 242
 - chronic obstructive pulmonary disease (COPD), 274–75
 - generic medications, 8, 17, 145–46, 358
 - heart failure, 177–79
 - hypertension, 391
 - ischemic heart disease, 145–47
 - obesity/overweight, 126–27
 - stroke, 163
 - Philippines
 - cost-effectiveness of interventions in, 12
 - priority-setting for treatments in, 378–80, 382
 - physical activity, 79–100
 - cardiometabolic disease and, 40, 47, 82–86
 - cardiovascular, respiratory, and related disorders (CVRDs) and, 28, 30–31
 - community-based care and, 312, 314

- coronary heart disease and, 82–83, 83*f*
- defined, 80*b*
- diabetes and, 84–85, 84–85*f*, 222–23
- diet and, 104–5
- economic costs of inactivity, 86–87
- exercise-based rehabilitation, 179–80
- gender issues, 91*b*
- hypertension and, 389
- integrated care and, 288
- interventions, 14, 87–91
 - community-based programs, 90*b*, 91
 - cost-effectiveness, 12, 91–92, 350, 354–55
 - primary health care, 88–89
 - public education campaigns, 89
 - sports systems and programs, 89, 91
 - transport and urban design, 89
 - whole-of-school programs, 88
- ischemic heart disease and, 136
- obesity/overweight and, 119–23, 125–28
- policy implications, 92–93
- prevalence and burden of inactivity, 80–81*f*, 80–82
- sedentary activity and sitting, 86
- stroke and, 83–84, 160–62, 165, 169
- physical therapy, 168
- phytoestrogens, 44
- pipe smoking, 68
- polychlorinated biphenyls, 44
- polypills, 146, 163–64, 395
- Popkin, B. M., 82
- population-level interventions
 - cost-effectiveness, 13, 349–51, 355, 361, 372
 - diabetes, 223
 - diet and nutrition, 101, 109–10
 - ischemic heart disease, 140, 144
 - obesity/overweight, 123, 131
- Poulter, Neil, 389
- Prabhakaran, Dorairaj, 1, 23, 57, 101, 173, 287, 389
- Practical Approach to Lung Health in South Africa (PALSA), 278*b*
- Pratt, Michael, 79, 87
- prediabetes, 12, 210, 213–14, 216–17, 342, 396
- pregnancy. *See also* gestational diabetes
 - cardiometabolic disease and, 37, 39, 41, 44, 46–49
 - cardiovascular, respiratory, and related disorders (CVRDs) and, 30, 31
 - Chagas disease and, 203
 - chronic respiratory diseases and, 267, 269
 - congenital heart disease and, 192–93
 - obesity/overweight and, 40–41, 41*f*, 47, 118
 - prenatal screening, 193–94, 193*t*
 - rheumatic heart disease and, 197
 - tobacco use and, 44
- prevalence
 - chronic kidney disease (CKD), 240
 - congenital heart disease (CHD), 191
 - diabetes, 48, 63, 109, 209–10, 214, 216, 288–90, 292, 381
 - end-stage renal disease (ESRD), 240
 - heart failure, 174, 176*t*
 - kidney disease, 235–36
 - obesity/overweight, 41, 118–19, 122–23, 315, 353
 - peripheral artery disease (PAD), 254, 255–56*f*
 - physical activity and inactivity, 80–81*f*, 80–82
- prevention
 - asthma, 269
 - chronic obstructive pulmonary disease (COPD), 269
 - congenital heart disease (CHD), 192–93
 - cost-effectiveness, 13–14
 - diabetes, 12, 213–14, 216–19, 221, 223
 - heart failure, 179
 - ischemic heart disease (IHD), 143–46
 - obesity/overweight, 117, 122–24, 130–31
 - rheumatic heart disease (RHD), 197, 198, 199, 201
 - statins as, 394–95
 - stroke, 161–65, 179, 357
 - antiplatelet therapy, 166
 - atrial fibrillation control, 164
 - blood pressure control, 166
 - carotid stenosis surgery, 166
 - community-based education, 164
 - cost-effectiveness, 165
 - digital health strategies, 164–65
 - family support, 166–67
 - high blood pressure, 163
 - homocysteine-lowering therapy, 166
 - lipid-lowering therapy, 166
 - pharmaceutical treatments, 163
 - polypill use, 163–64
 - primary, 162–65
 - secondary, 166–67
 - self-management, 166–67
 - sodium reduction, 163
 - tobacco use reduction, 162
- primary care centers, 12, 14–16. *See also* quality of care
 - chronic obstructive pulmonary disease (COPD) and, 15, 273–74
 - chronic respiratory diseases and, 270, 276–78, 277*t*, 278*b*
 - community-based care and, 305, 310
 - cost-effectiveness, 356–57
 - heart failure, 180–82
 - hypertension and, 397
 - improvement of, 3*b*

integrated care and, 295, 297
kidney disease and, 242, 244
obesity/overweight and, 129
physical activity and, 88–89
role of, 14–16
priority-setting for treatments, 375–88
 diabetes, 377–83, 379*t*, 380*f*, 382*b*
 dialysis, 383–86, 383*b*, 385*b*
Program for Appropriate Technology in
 Health (PATH), 320
Promotion of Breastfeeding Intervention Trial
 (Belarus), 47
prothrombotic state, 58*b*, 61
pulmonary thromboembolism, 276

Q

QALYs (quality-adjusted life years)
 cost-effectiveness of interventions and, 12, 354,
 356–57, 359–60
 diabetes and, 218–19
 heart failure and, 184
 hypertension and, 397
 ischemic heart disease and, 141–43, 145–47
 kidney disease and, 238, 245
 peripheral artery disease and, 258
 physical activity and, 91–92
 priority-setting for treatments and, 383–84
 rheumatic heart disease and, 201
quality of care, 327–48
 conceptual framework, 327, 328*t*
 patient-provider-level interventions, 332–43, 333*t*,
 334*f*, 335*b*, 336–40*t*, 341*f*, 342*b*
 acute phase, 332–34
 chronic phase, 334–43
 mobile communication technology and,
 341, 342*b*
 task-shifting, 341, 343
 system-level interventions, 328–31, 329–30*t*,
 331–32*b*
 acute phase, 328–29
 chronic phase, 329–31

R

Rajan, Vikram, 327
Rassi, Anis, 191
Rassi, Anis, Jr., 191
Rawal, Ishita, 57
Reduction of Atherothrombosis for Continued
 Health (REACH), 146
rehabilitation from stroke, 167–68, 167–68*t*
relative risk (RR)
 cardiometabolic disease, 38
 diet and nutrition, 104

heart failure and, 178–80, 183
integrated care and, 292–93
obesity/overweight and, 129
peripheral artery disease, 258
physical activity and, 83–84, 86
quality of care and, 337
stroke, 159–60, 163, 165
tobacco use and, 63, 65–68, 70
Remuzzi, Giuseppe, 235
renal replacement therapy (RRT), 237–38, 240,
 245–47, 245*f*, 383
respiratory diseases, chronic, 140, 263, 269–70,
 274, 276, 375
restrictive lung disease and fibrosis, 268, 275–76
retinopathy, 27, 215
RF. *See* rheumatic fever
RHD. *See* rheumatic heart disease
rheumatic fever (RF), 6, 197–98, 200, 357
rheumatic heart disease (RHD), 197–202
 burden of disease, 197
 cardiovascular, respiratory, and related disorders
 (CVRDs) and, 27
 heart failure and, 176–77
 hypertension and, 390
 interventions, 197–201, 198*t*
 cardiac surgery, 198–99
 community-based programs, 199
 cost-effectiveness, 13, 201–2, 357
 echocardiography, 199
 primary prevention, 197
 primordial prevention, 199
 public policy, 200, 200*t*
 secondary prevention, 198, 201
 surgical care platforms, 199–200
 mortality rates, 197
 natural history, 197
 pathogenesis, 197
 risk factors, 197
Riella, Miguel, 235
risk factors, 9–10
 alcohol use, 30
 asthma, 263–65
 cardiometabolic disease, 37–39, 38*f*, 41
 cardiovascular, respiratory, and related disorders
 (CVRDs), 28–32
 cardiovascular disease, 62–63
 Chagas disease, 27
 chronic obstructive pulmonary disease (COPD),
 263–67
 chronic respiratory diseases, 31, 33,
 263–68
 congenital heart disease, 26, 192–93, 196
 coronary heart disease, 29

- cost-effectiveness of interventions and, 355–58, 360–61
 - depression, 30
 - diabetes, 24–26, 160, 209–10, 215–17
 - diet and nutrition, 14, 102–5, 103–4*t*, 122, 161
 - disability, 25–28
 - dyslipidemia, 28
 - early childhood determinants, 30–31
 - heart failure, 174
 - high blood pressure, 29, 159
 - hypertension, 390–91, 397
 - integrated care and, 287–88, 292
 - ischemic heart disease, 136, 140
 - ischemic stroke, 30
 - kidney disease, 240–41
 - middle childhood determinants, 31–32
 - modifiable, 23, 28–30, 159–61, 192, 196
 - nonmodifiable, 27–28, 395
 - obesity/overweight, 29, 118–23, 119*f*, 129, 161
 - peripheral artery disease (PAD), 253, 254, 256, 260
 - physical inactivity, 29–30, 86, 161
 - rheumatic heart disease (RHD), 197
 - social and ecological determinants, 30–32, 33
 - stroke, 28–29, 65, 70, 83, 157, 159–61, 159–60*t*, 163–64, 166, 169
 - tobacco use, 28, 63, 65–66, 70, 160
 - rituximab, 242
 - Rivero-Ayerza, M., 180
 - Roth, Greg A., 173
 - Rotterdam Study, 66
 - Roux, L., 91
 - Roy, Ambuj, 57
 - RR. *See* relative risk
 - RRT. *See* renal replacement therapy
 - Rubinstein, Adolfo, 101
 - Russian Federation
 - ischemic heart disease in, 138
 - obesity/overweight in, 127, 130
 - stroke in, 161
 - tobacco use in, 68
 - Rwanda
 - heart failure in, 183, 184*t*
 - integrated care in, 294
- S**
- Sakuma, Yuna, 375
 - salt consumption, 16, 110, 163, 165, 353–54, 370*t*, 371–73
 - Sampson, Uchechukwu K. A., 253
 - screening
 - chronic kidney disease (CKD), 245, 246*b*
 - congenital heart disease (CHD), 193–94, 195–96
 - neonatal screening, 194
 - prenatal screening, 193–94, 193*t*
 - cost-effectiveness, 355–56
 - diabetes, 213, 215, 219, 396
 - dyslipidemia, 396
 - hypertension, 395–96
 - stroke, 161–62
 - secondary prevention
 - cardiovascular, respiratory, and related disorders (CVRDs), 28, 32
 - community-based care and, 312
 - cost-effectiveness, 14–15, 356–59
 - diabetes, 221
 - hypertension, 394, 397
 - ischemic heart disease, 135, 137, 139–41, 143, 145–47
 - peripheral artery disease, 258
 - physical activity, 79, 83
 - quality of care and, 331, 333
 - rheumatic heart disease, 197–203
 - stroke, 157, 161, 166, 169
 - tobacco use, 70
 - secondhand smoke, 28, 58–59, 61–62, 67, 70, 144
 - sedentary activity, 86
 - Seguro Popular (Mexico), 329–30
 - self-management interventions
 - chronic respiratory diseases, 275
 - community-based care and, 305, 312–16, 313*t*, 316*b*, 317*f*
 - cost-effectiveness, 315–16
 - diabetes, 212, 214, 217–18, 220
 - education in, 214, 312–13, 314–15
 - heart failure, 182
 - integrated care, 295
 - stroke, 166–67
 - target populations, 314
 - technology for, 315
 - theories of, 313–14
 - self-monitoring of blood glucose (SMBG), 12, 214, 217–18, 220
 - short message service (SMS), 315, 337, 340, 342
 - Siegel, Karen R., 209
 - Singapore, diet and nutrition in, 105–6
 - Sliwa, Karen, 173
 - Small, C. W., 162
 - SMBG. *See* Self-Monitoring of Blood Glucose
 - smokeless tobacco, 68–69
 - smoking. *See* tobacco use
 - sodium. *See* salt consumption
 - Soudarssanane, M. B., 201
 - South Africa
 - chronic respiratory diseases in, 278*b*
 - community-based care in, 306–8, 310

cost-effectiveness of interventions in, 12, 353, 356–58
 diabetes in, 213
 diet and nutrition in, 107, 110
 hypertension in, 397
 integrated care in, 290, 292–93
 ischemic heart disease in, 136, 140, 142, 144–46
 kidney disease in, 242, 244
 obesity/overweight in, 120, 124, 127, 130
 primary care centers in, 16
 priority-setting for treatments in, 378, 380, 385
 quality of care in, 343
 rheumatic heart disease in, 199, 201

South Asia. *See also specific countries*
 cardiometabolic disease in, 39
 cardiovascular, respiratory, and related disorders (CVRDs) in, 26, 28, 30
 chronic respiratory diseases in, 264
 community-based care in, 306
 diabetes in, 211, 216, 220
 heart failure in, 185
 hypertension in, 390
 ischemic heart disease in, 140–41
 kidney disease in, 244–45
 obesity/overweight in, 117
 rheumatic heart disease in, 197
 stroke in, 157
 tobacco use in, 68–70

South-East Asia. *See also specific countries*
 cardiovascular, respiratory, and related disorders (CVRDs) in, 26
 chronic respiratory diseases in, 264
 cost-effectiveness of interventions in, 350–51, 353, 359
 diabetes in, 211
 diet and nutrition in, 110
 hypertension in, 390
 ischemic heart disease in, 137–38
 kidney disease in, 240
 peripheral artery disease in, 256
 physical activity in, 80–81
 tobacco use in, 68

Spain
 cost-effectiveness of interventions in, 356
 ischemic heart disease in, 146
 priority-setting for treatments in, 382

speech therapy, 168
 sports systems and programs, 79–80, 85, 87–91
 Sri Lanka, kidney disease in, 240, 241*b*
 SSBs. *See* sugar and sugar-sweetened beverages
 statins. *See also* dyslipidemia
 cost-effectiveness, 12, 356–58, 360
 diabetes and, 219, 224
 ischemic heart disease and, 141–43, 145–46
 peripheral artery disease and, 254
 primary care centers and, 15
 for primary prevention, 394–95
 quality of care and, 333, 336, 341
 stroke and, 163, 165–66

ST-elevation myocardial infarction (STEMI), 136, 143, 329, 334, 359–60

Stevenson, C. R., 290

streptococcal pharyngitis, 197, 200–201

stroke, 157–72. *See also* ischemic stroke
 burden of disease, 157–59
 cardiometabolic disease and, 37
 cardiovascular, respiratory, and related disorders (CVRDs) and, 23–24, 26–30
 community-based care and, 309, 312
 cost-effectiveness of interventions, 12, 356–58, 360, 369, 371–72
 diabetes and, 160, 210–11, 214
 diagnosis, 162
 diet and, 103–4, 161
 disability and, 158
 hypertension and, 159, 390–91, 394–95, 397
 ischemic heart disease and, 136–37
 modifiable risk factors, 159–61
 mortality and morbidity, 26, 27*f*, 157, 158*m*, 160, 162, 211, 389
 obesity/overweight and, 161
 peripheral artery disease and, 253–54
 physical activity and, 82, 83–84, 86–87, 161
 prevention, 161–65, 179, 357
 antiplatelet therapy, 166
 atrial fibrillation control, 164
 blood pressure control, 166
 carotid stenosis surgery, 166
 community-based education, 164
 cost-effectiveness, 165
 digital health strategies, 164–65
 family support, 166–67
 high blood pressure, 163
 homocysteine-lowering therapy, 166
 lipid-lowering therapy, 166
 pharmaceutical treatments, 163
 polypill use, 163–64
 primary, 162–65
 secondary, 166–67
 self-management, 166–67
 sodium reduction, 163
 tobacco use reduction, 162

primary care centers and, 15
 quality of care and, 327, 329, 331, 333, 341
 risk factors, 28–29, 65, 70, 83, 159–60*t*, 159–61, 163–64

- screening, 161–62
 - surveillance, 161
 - tobacco use and, 63–65, 67–68, 160, 162
 - treatment, 165–66
 - cognitive rehabilitation, 168
 - cost-effectiveness, 168
 - physical, occupational, or movement therapy, 168
 - rehabilitation, 167–68, 167–68*t*
 - speech therapy, 168
 - Stroke Riskometer (mobile app), 165
 - structural heart diseases, 191–208
 - Chagas disease, 202–4. *See also* Chagas disease
 - congenital heart disease, 191–96. *See also* congenital heart disease
 - rheumatic heart disease, 197–202. *See also* rheumatic heart disease
 - Sub-Saharan Africa. *See also specific countries*
 - community-based care in, 306, 311
 - cost-effectiveness of interventions in, 350–51, 359
 - diabetes in, 211–12
 - heart failure in, 174, 176–77, 181
 - hypertension in, 390
 - ischemic heart disease in, 138–41
 - kidney disease in, 245
 - peripheral artery disease in, 254, 256–57, 259–60
 - quality of care in, 331
 - rheumatic heart disease in, 197, 199, 202
 - tobacco use in, 68
 - sugar and sugar-sweetened beverages (SSBs), 11–13, 17, 102–9, 119, 123–28, 131, 222, 266, 352–53
 - Suhrcke, Marc, 101, 349
 - suicide, 288
 - Sustainable Development Goals, 2, 23, 375
 - Sustainable Kidney Foundation, 237*b*
 - Sweden
 - diet and nutrition in, 108
 - physical activity in, 88
 - Switzerland
 - diabetes in, 212
 - diet and nutrition in, 108
 - integrated care in, 293
 - obesity/overweight in, 125
 - physical activity in, 79
 - sympathetic stimulation, 58*b*
 - system-level interventions
 - acute phase, 328–29
 - chronic phase, 329–31
 - quality of care in, 328–31, 329–30*t*, 331–32*b*
- T**
- Taiwan
 - integrated care in, 291, 293
 - obesity/overweight in, 121, 125
 - Tandon, Nikhil, 209
 - Tanzania
 - cost-effectiveness of interventions in, 369
 - health care costs in, 8
 - kidney disease in, 237*b*, 238–39
 - task-shifting
 - community-based health care, 305–12, 307–9*t*, 311*b*
 - patient-provider-level interventions, 341, 343
 - taxation
 - of tobacco use, 9, 13, 16, 144–45, 162, 350–52, 355, 372–73
 - of unhealthy beverages and foods, 11–12, 108–9, 124
 - telemedicine, 315
 - television watching, 79, 106, 120–21, 125, 127–28
 - Thailand
 - community-based care in, 316
 - ischemic heart disease in, 141, 144–45
 - kidney disease in, 245, 247
 - obesity/overweight in, 125
 - primary care centers in, 15
 - priority-setting for treatments in, 375, 378
 - stroke in, 163, 167–68
 - Thai Registry in Acute Coronary Syndrome (TRACS), 143
 - thirdhand smoke, 67–68
 - Thomas, Bernadette, 235
 - thrombolysis, 143, 254, 329, 333, 360
 - thrombosis, 60–61, 164
 - tiotropium, 272
 - tissue plasminogen activator (tPA), 165
 - tobacco use, 57–78
 - aortic artery disease and, 66
 - arrhythmia and, 66
 - cardiovascular, respiratory, and related disorders (CVRDs) and, 26, 28–30, 31–32
 - cardiovascular disease and
 - health outcomes, 63–67, 64*b*, 64*f*
 - mortality rates, 64
 - pathophysiology and mechanisms, 58–62, 59–60*f*
 - risk factors, 62–63
 - carotid and cerebrovascular diseases and, 65
 - cessation benefits, 69–70, 70*b*
 - chronic kidney disease and, 66–67
 - chronic respiratory diseases and, 265, 271
 - community-based care and, 308
 - coronary heart disease and, 65
 - cost-effectiveness of interventions, 350–52, 351*t*, 353, 355, 360, 370–71, 370*t*
 - diabetes and, 63, 210, 215
 - diet and, 110
 - dyslipidemia and, 62
 - forms of, 67*t*, 68–69

global mandate for reducing, 57–58
 health consequences of, 351
 heart failure and, 65
 hypertension and, 62–63, 397
 ischemic heart disease and, 142, 143–45
 maternal smoking and cardiometabolic disease, 39, 44
 obesity/overweight and, 130
 peripheral artery disease and, 66, 255–56
 secondhand smoke, 67
 smoking cessation, 62, 144, 221, 224, 258, 263, 265, 336, 391
 socioeconomic variables, 69
 stroke and, 65, 159–60, 162, 169
 taxation of, 9, 13, 16, 144–45, 162, 350–52, 355, 372–73
 thirdhand smoke, 67–68
 TRACS (Thai Registry in Acute Coronary Syndrome), 143
 Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement (1995), 145
 Training Programme for Caregivers of Inpatients after Stroke, 167
 trans fats consumption, 14, 102, 104, 106, 108, 353–54
 transportation systems design, 89
 treatment

- congenital heart disease (CHD), 194–95
 - cost-effectiveness, 195–96
- end-stage renal disease (ESRD), 242–45
- hypertension, 330, 370, 372
- kidney disease, 383–86, 383*b*, 385*b*
- priority-setting for, 383–86, 383*b*, 385*b*
- stroke, 165–66
 - cognitive rehabilitation, 168
 - cost-effectiveness, 168
 - physical, occupational, or movement therapy, 168
 - rehabilitation, 167–68, 167–68*t*
 - speech therapy, 168

 TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement (1995), 145
 Trivandrum heart failure registry, 181*b*
 tuberculosis

- chronic respiratory diseases and, 264, 267–69, 275
- cost-effectiveness of interventions, 371
- diabetes and, 288–92, 289*f*, 290–91*t*
- integrated care and, 287–92, 294
- kidney disease and, 244

 Turkey

- community-based care in, 315
- obesity/overweight in, 120
- priority-setting for treatments in, 378–81

U

Uganda

- community-based care in, 306
- surgical treatment in, 10

 UHC. *See* universal health coverage
 Ukraine, ischemic heart disease in, 138
 United Kingdom

- cardiometabolic disease in, 37–38, 41, 48
- chronic respiratory diseases in, 263, 268
- community-based care in, 311
- congenital heart disease in, 195
- cost-effectiveness of interventions in, 358
- hypertension in, 395
- obesity/overweight in, 118, 124–26, 130
- peripheral artery disease in, 258
- physical activity in, 82, 87–89
- primary care centers in, 14
- priority-setting for treatments in, 382
- stroke in, 164
- tobacco use in, 62, 66

 United Kingdom National Institute for Health and Care Excellence, 377
 United Nations, 91–92, 393
 United Nations High-level Meeting on Non-Communicable Diseases, 295
 United States

- Chagas disease in, 203
- community-based care in, 311
- congenital heart disease in, 191, 195
- cost-effectiveness of interventions in, 357–58, 369
- diabetes in, 209–10, 213, 216–18
- diet and nutrition in, 101, 105, 107–9
- heart failure in, 179
- integrated care in, 287, 291–95
- ischemic heart disease in, 141, 143–44, 146–47
- kidney disease in, 238, 240, 242, 244–46
- obesity/overweight in, 117–22, 124–26
- physical activity in, 82, 88
- priority-setting for treatments in, 382
- rheumatic heart disease in, 199
- stroke in, 159, 164

 universal health coverage (UHC), 4, 16–17, 23, 344–45, 369, 371–72, 376, 385
 University of Colorado at Denver, 241*b*
 urban planning and design, 89, 120, 126
 Uruguay

- ischemic heart disease in, 144
- kidney disease in, 244
- priority-setting for treatments in, 384

V

Vaca, Claudia, 375
 Vaidyanathan, B., 191

van Pelt, Maurits, 321
Vedanthan, Rajesh, 327
vegetables, 13, 28, 32–33, 103–8, 124–26, 129, 131, 160–62, 169, 266
Venezuela, República Bolivariana de
 insulin costs in, 10
 priority-setting for treatments in, 378
Verguet, Stéphane, 369
Vietnam
 chronic respiratory diseases in, 264
 congenital heart disease in, 194
 cost-effectiveness of interventions in, 11, 351, 360
 tobacco use in, 68

W

waterpipe smoking, 68
Watkins, David A., 1, 23, 191, 201, 202, 369
Webb, Michael, 101
Weber, Mary Beth, 305
weight. *See* birth weight; body mass index; obesity/overweight
weight-loss diets, 126
Whitsel, Laurie, 101
WHO. *See* World Health Organization
WHO Choosing Interventions that are Cost-Effective (WHO-CHOICE), 110
WHO Study on Prevention of Recurrences of Myocardial Infarction and Stroke (WHO-PREMISE), 145
Will, J. C., 63
women. *See* gender issues; pregnancy
Wong, Gary, 263
worksite interventions, 105, 129–30

World Health Assembly, 57
World Health Organization (WHO)
 on cardiovascular, respiratory, and related disorders (CVRDs), 23–31
 on chronic respiratory diseases, 277–78
 on community-based care, 308–11
 on congenital heart disease, 191–92
 on cost-effectiveness of interventions, 13–15, 353–57, 369–70
 on diabetes, 211
 on diet and nutrition, 107–9
 on heart failure, 174–75, 182*b*
 on hypertension, 390–91, 396–97
 on integrated care, 288–90
 on ischemic heart disease, 145
 on obesity interventions, 117–18, 129–30, 130*t*
 on physical activity, 79–81, 92
 on priority-setting for treatments, 376–79
 on rheumatic heart disease, 197–201
 on tobacco use, 57
World Medical Association, 311
Wu, Yangfeng, 1, 157

Y

Yan, Lijing L., 157
Yancy, Clyde W., 173
Yeates, Karen, 237*b*

Z

Zhang, Ping, 209
Zhao, Dong, 157
Zhu, Yishan, 157